Pharmaceutical composition for cancer treatment comprising a fusion protein comprising il-12 and an Anti-fap

By developing a combination of fusion proteins containing IL-12 and FAP antigen binding sites and anticancer agents, the toxicity and insufficient effect of IL-12 single drug in treating cancer was solved, and tumor-specific accumulation was achieved and The synergistic anti-cancer effect has significantly improved the therapeutic effect.

CN119072325APending Publication Date: 2024-12-03ZHINAFU PHARM TECH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202380033739.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-11
Filing Date
2023-02-10
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing IL-12 as a single drug has systemic cytokine-related toxicity in the treatment of cancer and has limited therapeutic effects on tumors.

Method used

Develop an anticancer drug composition containing a fusion protein containing IL-12 or a variant thereof and an antigen binding site specifically binding to FAP, as well as an anticancer agent to achieve the Tumor-specific accumulation and anti-cancer effects of IL-12.

Benefits of technology

It reduces systemic toxicity, improves tumor-specific anti-cancer effects, and significantly enhances the anti-cancer efficacy through the synergistic effect of fusion proteins and anti-cancer agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072325A_ABST
    Figure CN119072325A_ABST
Patent Text Reader

Abstract

The present invention provides a combination therapeutic agent of: a fusion protein comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP; and an anti-cancer agent. The bispecific antibody exhibits an anti-cancer effect through IL-12, and in particular, if an anti-FAP antibody is implemented in one antibody, cancer can be effectively treated by targeting FAP highly specifically expressed in a tumor and specifically localizing IL-12 to a tumor site. When the fusion protein is administered in combination with a known anti-cancer agent, a synergistic effect exists in anti-cancer treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to an anticancer pharmaceutical composition, which comprises a novel fusion protein containing IL-12 or a variant thereof and an anti-FAP antibody, and an anticancer agent. Background Art

[0002] Interleukin-12 (IL-12) is a representative inflammatory cytokine that plays a vital role in the effective induction of cellular immune responses. IL-12 is a heterodimeric protein that contains 40kDa (p40) and 35kDa (p35) subunits linked by disulfide bonds and is produced by activated macrophages, monocytes, dendritic cells, and activated B lymphocytes. IL-12 can enhance T-helper 1 cell immunity, increase the cytotoxicity of cellular T lymphocytes, and inhibit angiogenesis. In general, IL-12 activates the production of IFN-γ in T cells and NK cells.

[0003] Local expression of IL-12 sensitizes tumor cells to T cell-mediated cytotoxicity, leading to tumor growth inhibition and the establishment of humoral immunity. However, a disadvantage of the clinical use of IL-12 is that systemic cytokine-related toxicity may occur after administration. These clinical results indicate the limitations of IL-12 as a single agent for the treatment of cancer.

[0004] On the other hand, fibroblast activation protein alpha (FAP) is a gelatinase expressed on activated fibroblasts. It is known that FAP is expressed in cancer-associated fibroblasts of various human cancers, including prostate cancer and pancreatic cancer, in excess of 90%. Therefore, interest in developing immunotherapies targeting FAP-expressing cells has increased rapidly recently (Fang J et al., Mol. Ther. Oncolytics, 3: 16007, 2016). Summary of the invention

[0005] Technical issues

[0006] Therefore, the present inventors have studied and developed a pharmaceutical composition having an effective anticancer effect. As a result, the present inventors discovered a synergistic anticancer effect when a fusion protein comprising IL-12 and an anti-FAP antibody is administered together with an anticancer agent, thereby completing the present invention.

[0007] Solutions to the problem

[0008] In one aspect of the present invention, a pharmaceutical composition for treating cancer is provided, which comprises: a fusion protein comprising a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP (fibroblast activation protein α); and an anticancer agent.

[0009] In another aspect of the present invention, a kit for preventing or treating cancer is provided, the kit comprising: a fusion protein comprising a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP; and an anticancer agent as an active ingredient.

[0010] Effects of the Invention

[0011] A fusion protein comprising IL-12 and an antigen binding site that specifically binds to FAP may exhibit an anti-cancer effect through IL-12. In addition, it was found that when an anti-FAP antibody is implemented in one antibody, IL-12 specifically accumulates in tumors with high FAP expression, thereby reducing systemic toxicity and exhibiting a tumor-specific anti-cancer effect. That is, by specifically targeting FAP that is highly expressed in tumors and specifically localizing IL-12 to the tumor site, cancer can be effectively treated. In particular, when the fusion protein and the anticancer agent are administered together, there is a synergistic anti-cancer effect. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 Shown are the results obtained by SDS-PAGE identification of T1.01, T1.02, T1.03, T1.04, T1.05, T1.06, and T1.07, according to the embodiments.

[0013] Figure 2 The results obtained by SDS-PAGE identification of T1.08, T1.09, T1.10, T1.11, T1.12, T1.13, T1.14 and T1.15 according to the embodiment are shown.

[0014] Figure 3 The results obtained by SDS-PAGE identification of T1.16, T1.17, T1.18, T1.19 and T1.21 according to the embodiment are shown.

[0015] Figure 4 Shown are the results obtained by identifying T1.01m, T1.02m, T1.03m, T1.04m, T1.05m, T1.06m, and T1.07m by SDS-PAGE according to the embodiment.

[0016] Figure 5The results obtained by identifying T1.08m, T1.09m, T1.10m, T1.11m, T1.12m, T1.13m and T1.15m by SDS-PAGE according to the embodiment are shown.

[0017] Figure 6 Shown are the results obtained by identifying T1.16m, T1.17m, T1.18m, T1.19m, T1.20m, T1.21m, and T1.22m by SDS-PAGE according to the embodiment.

[0018] Figure 7 Shown is a graph showing the binding affinity of T1.01 and T1.02 to human recombinant FAP (rhFAP) by surface plasmon resonance analysis method.

[0019] Figure 8 A graph showing the binding affinity of T1.03 to human recombinant FAP by surface plasmon resonance analysis is shown.

[0020] Fig. 9 A graph showing the extent of binding of T1.04 and T1.05 to human recombinant FAP by surface plasmon resonance analysis is shown.

[0021] Fig.10 A graph showing the extent of binding of T1.06 and T1.07 to human recombinant FAP by surface plasmon resonance analysis is shown.

[0022] Fig.11 A graph showing the extent of binding of T1.08 and T1.09 to human recombinant FAP by surface plasmon resonance analysis is shown.

[0023] Fig.12 A graph showing the extent of binding of T1.10 and T1.11 to human recombinant FAP by surface plasmon resonance analysis is shown.

[0024] Fig.13 A graph showing the binding affinity of T1.01m and T1.02m to mouse recombinant FAP by surface plasmon resonance analysis method is shown.

[0025] Fig.14 A graph showing the binding affinity of T1.03m to mouse recombinant FAP by surface plasmon resonance analysis is shown.

[0026] Fig.15 Shown are graphs showing the binding affinity of T1.12, T1.01, T1.02, and T1.03 to HEK293-hFAP cells and HEK293 cells by flow cytometry.

[0027] Fig.16 Shown are graphs showing the binding affinities of T1.12m, T1.01m, T1.02m, and T1.03m to B16F10-mFAP cells and B16F10 cells by flow cytometry.

[0028] Fig.17 A graph showing the binding affinity of T1.01, T1.02, T1.03, and T1.12 to IL-12 receptor β1 by enzyme-linked immunosorbent assay is shown.

[0029] Fig.18 A graph showing the results of detecting T1.01m, T1.02m, T1.03m, and T1.12m and IL-12 activity by absorbance in HEKblue reporter cells.

[0030] Fig.19 A graph showing the activity of T1.01, T1.02, T1.03, and T1.12 and IL-12 by the signaling capacity of human T cells is shown.

[0031] Fig. 20 Shown is a graph showing the IL-12 activity of T1.01, T1.02 and T1.03 through human T cell signaling capacity in the presence of low molecular weight heparin (LMWH).

[0032] Fig.21 A graph showing the results of measuring the ability of human T cells to secrete the cytokine IFN-γ by T1.12, T1.01, T1.02, and T1.03.

[0033] Fig. 22 A graph showing the results of measuring the ability of human NK cells to secrete the cytokine IFN-γ by T1.12, T1.01, T1.02, and T1.03.

[0034] Fig.23 A graph showing the tumor growth inhibitory ability of T1.01m and T1.02m by measuring the change in tumor size of a mouse tumor model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colorectal cancer cell line CT26.

[0035] Fig.24 Results obtained by measuring the tumor size of each subject to identify the tumor growth inhibitory ability of T1.01m and T1.02m in a mouse tumor model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colorectal cancer cell line CT26 are shown.

[0036] Fig.25Shown is a graph showing the tumor inhibitory ability of administering each concentration of T1.01m and T1.02m by measuring changes in tumor size implanted in mouse FAP-overexpressing colorectal cancer cell line CT26 in a mouse tumor model.

[0037] Fig.26 A graph showing the change in CT26 tumor size after tumor rechallenge model was established by transplantation of CT26 cells and 4T1 cells into mice, wherein a complete response was achieved in the mouse tumor model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colorectal cancer cell line CT26.

[0038] Fig. 27 A graph showing the change in 4T1 tumor size after tumor rechallenge model was established by transplantation of CT26 cells and 4T1 cells into mice, in which a complete response was achieved in the mouse tumor model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colorectal cancer cell line CT26.

[0039] Fig.28 A graph showing the tumor growth inhibitory ability by administering different concentrations of T1.01m, T1.02m, and T1.03m to each subject by measuring the tumor size of each subject in a mouse model implanted with mouse FAP-overexpressing CT26 cells is shown.

[0040] Fig.29 A graph showing the tumor growth inhibitory ability of T1.03m by administering each concentration to each subject by measuring the change in tumor size of each subject in a mouse model implanted with mouse FAP-overexpressing CT26 cells is shown.

[0041] Fig.30 Shown is a graph showing the tumor growth inhibitory ability of administering each concentration of T1.03m by measuring the change in tumor size of each subject in a mouse model implanted with mouse FAP-overexpressing B16F10 cells.

[0042] Fig.31 A graph showing the tumor growth inhibitory ability of each concentration of T1.03m administered is shown, in which the change in tumor size of each subject was measured in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and lung cancer cell line LLC1.

[0043] Fig.32 A graph showing the results obtained by measuring tumor size at the 10-day time point after simultaneous administration of T1.16m, T1.17m, T1.03m, or T1.16m and T1.17m treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and lung cancer cell line LLC1.

[0044] Fig.33a Shown is a graph showing the results obtained by measuring tumor size at the 9-day time point after treatment with T1.03m and aPD-L1, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and lung cancer cell line LLC1.

[0045] Fig.33b Shown is a graph showing the results obtained by measuring tumor size at the 9-day time point after treatment with T1.03m and aCTLA-4, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and lung cancer cell line LLC1.

[0046] Fig.33c A graph showing the results obtained by measuring tumor size at a time point of 9 days after treatment with T1.03m and aPD-1, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and lung cancer cell line LLC1.

[0047] Fig.34a A graph showing the results obtained by measuring tumor size at the 16-day time point after treatment with T1.03m and aPD-L1, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0048] Fig.34b Shown are graphs showing the results over time obtained by measuring tumor size up to 16 days after separate or simultaneous administration of T1.03m and aPD-L1 treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0049] Fig.35a A graph showing the results obtained by measuring tumor size at the time point of 11 days after treatment with T1.03m and aPD-L1, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0050] Fig.35b Shown are graphs showing the results over time obtained by measuring tumor size up to 11 days after separate or simultaneous administration of T1.03m and aPD-L1 treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0051] Fig.36aShown is a graph showing the results obtained by measuring tumor size at the 10-day time point after treatment with T1.03m and aTIGIT, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0052] Fig.36b Shown are graphs showing the results over time obtained by measuring tumor size up to 10 days after separate or simultaneous administration of T1.03m and aTIGIT treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0053] Fig.37a Shown is a graph showing the results obtained by measuring tumor size at the time point of 10 days after treatment with T1.03m and aLAG-3, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0054] Fig.37b Shown are graphs showing the results over time obtained by measuring tumor size up to 10 days after separate or simultaneous administration of T1.03m and aLAG-3 treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0055] Fig.38a Shown is a graph showing the results obtained by measuring tumor size at the 10-day time point after treatment with T1.03m and aTIM-3, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0056] Figure 38b Shown are graphs showing the results over time obtained by measuring tumor size up to 10 days after separate or simultaneous administration of T1.03m and aTIM-3 treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0057] Fig.39a Shown is a graph showing the results obtained by measuring tumor size at the time point of 11 days after treatment with T1.03m and cyclophosphamide, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0058] Fig.39bShown are graphs showing the results over time obtained by measuring tumor size up to 11 days after separate or simultaneous administration of T1.03m and cyclophosphamide treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0059] Fig.40a Shown is a graph showing the results obtained by measuring tumor size at the time point of 11 days after treatment with T1.03m and fluorouracil, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0060] Fig.40b Shown are graphs showing the results over time obtained by measuring tumor size up to 11 days after separate or simultaneous administration of T1.03m and fluorouracil treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0061] Fig.41a Shown is a graph showing the results obtained by measuring tumor size at the time point of 11 days after treatment with T1.03m and paclitaxel, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0062] Fig.41b Shown is a graph showing the results over time obtained by measuring tumor size up to 11 days after treatment with T1.03m and paclitaxel, either separately or simultaneously, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0063] Fig.42a Shown is a graph showing the results obtained by measuring tumor size at the time point of 11 days after treatment with T1.03m and Camptosar, respectively, in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0064] Figure 42b Shown is a graph showing the results over time obtained by measuring tumor size up to 11 days after separate or simultaneous administration of T1.03m and Camptosar treatment in a mouse model co-injected with mouse FAP-overexpressing fibroblasts NIH-3T3 and colon cancer cell line MC38.

[0065] Fig.43Schematic diagrams of an anti-FAP / IL-12 fusion protein (first from the left), an anti-FAP / IL-12 fusion protein with dual variable domains (second), an anti-FAP / IL-12 dual antibody bound to a FAP-specific single-chain variable fragment (scFv) (third and fourth), and an anti-FAP / IL-12 fusion protein in which IL-12 is bound to the C-terminus of Fc (fifth) are shown.

[0066] Fig.44 Schematic diagrams of FAP-specific Fab / FAP-specific single-chain variable fragment (scFv) and IL-12 fusion protein (left), fusion protein dimer comprising FAP-specific Fab and IL-12 (middle), and FAP-specific single-chain variable fragment (scFv) and IL-12 fusion protein (right) are shown.

[0067] Mode for Carrying Out the Invention

[0068] Combination therapy comprising a fusion protein containing IL-12 and an anti-FAP antibody and an anticancer agent

[0069] In one aspect of the present invention, a pharmaceutical composition for preventing or treating cancer is provided, which comprises: a fusion protein comprising a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP (fibroblast activation protein α); and an anticancer agent.

[0070] The fusion protein exhibits anti-cancer effects through IL-12, and not only exhibits tumor-specific anti-cancer effects by specifically accumulating IL-2 in tumors with high FAP expression, but also reduces systemic toxicity, and can be used in combination with various conventionally used anti-cancer treatments. Specifically, the conventional treatments that can be used in combination can be selected from the group consisting of chemical anticancer agents used for chemotherapy, oncolytic viruses, immune checkpoint inhibitors, and combinations thereof.

[0071] Anticancer Agents

[0072] As used herein, the term "chemical anticancer agent" also refers to an antitumor agent or a cytotoxic agent. It is a general term for drugs that exhibit anticancer activity by directly affecting DNA and blocking the replication, transcription, and translation processes of DNA, or interfering with the synthesis of nucleic acid precursors in metabolic pathways and inhibiting cell division. The antitumor agent acts not only on tumor cells, but also on normal cells and exhibits cytotoxicity. Chemical anticancer agents can be used for maintenance therapy. In addition, as used herein, the term "maintenance therapy" refers to the treatment of cancer with drugs after the initial anticancer treatment, and refers to a treatment method performed to prevent or delay the recurrence of cancer.

[0073] The chemical anticancer agent may be any one selected from the group consisting of an alkylating agent, a microtubule inhibitor, an antimetabolite, and a topoisomerase inhibitor.

[0074] In one embodiment, the alkylating agent may be cyclophosphamide or cisplatin. The microtubule inhibitor may be paclitaxel. The antimetabolite may be fluorouracil or gemcitabine. The topoisomerase inhibitor may be Camptosar or doxorubicin.

[0075] As used herein, the term "oncolytic virus therapy" is a treatment that kills cancer by inserting specific genes that target cancer cells into a proliferative and infectious virus. The oncolytic virus therapy can be Talimogene Laherparepvec (T-VEC).

[0076] As used herein, the term "immune checkpoint inhibitor" refers to a substance that inhibits the activity of immune checkpoint proteins, which inhibit the differentiation, proliferation, activity of immune cells and are known to eliminate cancer cells by preventing cancer cells from exercising functions to evade the immune system.

[0077] In one embodiment, the immune checkpoint inhibitor can be any one selected from the group consisting of anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-TIM3 antibody, anti-TIGIT antibody and anti-LAG3 antibody.

[0078] In one embodiment, the immune checkpoint inhibitor may be any one selected from the group consisting of ipilimumab, pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab, and durvalumab.

[0079] The fusion protein can be used in combination with an anticancer vaccine, etc. Furthermore, the anticancer agent is not only the above-mentioned anticancer agent but can also be used together with an anticancer vaccine, etc.

[0080] In addition, the anticancer agent may include one or more anticancer agents. Specifically, the fusion protein can be used with two anticancer agents. For example, a chemical anticancer agent and an anticancer virus; an anticancer virus and an immune checkpoint inhibitor; and a chemical anticancer agent and an immune checkpoint inhibitor.

[0081] In addition, the fusion protein can be used together with three anticancer agents. Anticancer agents different from the above two anticancer agents can be further included and used. In one embodiment, the anticancer agent can be a chemical anticancer agent, an anticancer virus, and an immune checkpoint inhibitor.

[0082] Anti-cancer maintenance use of fusion proteins

[0083] Another aspect of the present invention provides a composition for maintaining anti-cancer, the composition comprising: a fusion protein as an active ingredient, the fusion protein comprising a first monomer containing IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP.

[0084] The fusion proteins are described below.

[0085] As mentioned above, "maintaining anti-cancer" refers to treating cancer after initial anti-cancer treatment. In particular, it is a treatment method that improves the effectiveness of cancer treatment by preventing or delaying cancer recurrence.

[0086] In this case, at least one additional anticancer agent may be included for maintenance therapy. In this case, the anticancer agent is as described above.

[0087] Kit comprising a fusion protein and an anticancer agent

[0088] Another aspect of the present invention provides a kit for preventing or treating cancer, the kit comprising: a fusion protein comprising a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP; and an anticancer agent as an active ingredient.

[0089] Fusion protein containing IL-12 and FAP antibody

[0090] The fusion protein comprising IL-12 or its variant and an antigen binding site that specifically binds to FAP may comprise an immunoglobulin Fc region. In this case, IL-12 or its variant may be a variant having low heparin binding ability.

[0091] In one embodiment, the fusion protein may be a fusion protein including a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP.

[0092] In another embodiment, the fusion protein may be a dimer of a fusion protein comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP.

[0093] IL-12 or its variants

[0094] As used herein, the term "IL-12" is a heterodimeric cytokine composed of p35 and p40 subunits encoded by two independent genes, IL-12A and IL-12B, respectively. IL-12 is produced by antigen presenting cells (such as macrophages) and binds to receptors on the cell surface of activated T cells and NK cells. IL-12 promotes the proliferation of T cells and NK cells and enhances the cytotoxic effects of T cells, NK cells and macrophages. In addition, IL-12 induces the production of IFN-γ, TNF-α and GM-CSF, and induces the activation of Th1 cells. On the other hand, IL-12 binds to the IL-12 receptor, and the IL-2 receptor is a heterodimeric receptor formed by IL-12Rβ1 and IL-12Rβ2.

[0095] As used herein, the term "variant" of IL-12 includes amino acid sequences having similar or identical functions to wild-type IL-12 proteins. Specifically, the amino acid sequences constituting the p35 and p40 subunits of IL-12 may have substitutions, insertions or deletions compared to the wild type.

[0096] IL-12 or variants thereof may include IL-12A(p35) or variants thereof, and IL-12B(p40) or variants thereof.

[0097] Furthermore, IL-12 or a variant thereof may include a structure in which IL-12A or a variant thereof, IL-12B or a variant thereof is bound by a peptide linker.

[0098] In one embodiment, IL-12 or a variant thereof may be a fusion protein comprising the following structural formula (I) or (II):

[0099] N'-Y-[Connector (1)]oZ-C'(I)

[0100] N'-Z-[Linker (1)]oY-C'(II)

[0101] In structural formulas (I) and (II),

[0102] N' can be the N terminus of the fusion protein,

[0103] C' can be the C-terminus of the fusion protein,

[0104] Y may be IL-12A or a variant thereof,

[0105] Z may be IL-12B or a variant thereof,

[0106] Linker (1) may be a peptide linker, and

[0107] o can be 0 or 1.

[0108] One embodiment of IL-12 or its variant may be a structure in which IL-12B or its variant, a peptide linker, and IL-12A or its variant are sequentially connected at the N-terminus. In addition, one embodiment of IL-12 or its variant may be a structure in which IL-12A or its variant, a peptide linker, and IL-12B or its variant are sequentially connected at the N-terminus.

[0109] As used herein, the term "IL-12A" is the 35 kDa subunit of IL-12 (p35), which is bound to the 40 kDa subunit of IL-12 (p40) via a disulfide bond to produce the active cytokine.

[0110] The amino acid sequence of IL-12A may be a sequence described in GenBank Accession No. AAK84425 (for the amino acid sequence of mouse p35, see GenBank Accession No. AAA39292). In addition, the IL-12A (p35) gene is a sequence encoding an IL-12A subunit, and may be a nucleotide sequence corresponding to the coding sequence (CDS) in the sequence described in GenBank Accession No. AF404773 (for the mouse sequence, see GenBank Accession No. M86672).

[0111] As used herein, the term "variant" of IL-12A includes an amino acid sequence having similar or identical functions to a wild-type IL-12A protein. Specifically, this means that the amino acid sequence of IL-12A has a substitution, insertion or deletion compared to the wild type. Specifically, the IL-12A variant may be a fragment of IL-12A, and may have an amino acid sequence in which the 1st to 22nd amino acids of SEQ ID NO: 122 are deleted. More specifically, the variant of IL-12A may have the amino acid sequence of SEQ ID NO: 75.

[0112] In addition, the IL-12A used in one embodiment of the present invention may be the amino acid sequence of SEQ ID NO: 75 which is human IL-12A. In one embodiment, the mouse IL-12A may be the amino acid sequence of SEQ ID NO: 87.

[0113] As used herein, the term "IL-12B" refers to the 40 kDa subunit (p40) of IL-12, which is combined with the 35 kDa subunit (p35) of IL-12 through a disulfide bond to form IL-12, and is also combined with the subunit p19 of IL-23 to form IL-23. On the other hand, IL-12B is also known as natural killer cell stimulator 2.

[0114] The amino acid sequence of "IL-12B" may be the amino acid sequence described in GenBank Accession No. AAD56386 (see GenBank Accession No. AAA39296 for the amino acid sequence of mouse p40). In addition, the IL-12B (p40) gene is a sequence encoding an IL-12B subunit and may be a nucleotide sequence corresponding to the coding sequence (CDS) of a sequence described in GenBank Accession No. AF180563 (see GenBank Accession No. M86671 for the mouse sequence).

[0115] In addition, the IL-12B used in one embodiment of the present invention may be human IL-12B, and specifically, IL-12B may be the amino acid sequence of SEQ ID NO: 74. In one embodiment, mouse IL-12B may have the amino acid sequence of SEQ ID NO: 86.

[0116] As used herein, the term "variant" of IL-12B includes an amino acid sequence having similar or identical functions to a wild-type IL-12B protein. Specifically, this means that the amino acid sequence of IL-12B has substitutions, insertions or deletions compared to the wild-type.

[0117] Specifically, the IL-12B variant may be a variant in which the 1st to 22nd amino acids of SEQ ID NO: 121 are deleted. More specifically, the IL-12B variant may be a variant in which 1 to 8 amino acids are substituted in the sequence of SEQ ID NO: 74. In addition, the IL-12B variant may be a variant in which the 1st to 22nd amino acids of SEQ ID NO: 123 are deleted. More specifically, the IL-12B variant may be a variant in which at most 1 to 8 amino acids are substituted in the sequence of SEQ ID NO: 86.

[0118] The variant of IL-12B(p40) may be a variant in which an amino acid involved in heparin binding to IL-12 is substituted.

[0119] In one embodiment, the variant of IL-12B (p40) may be a form in which the lysine (K) that binds to heparin in IL-12B is substituted by another amino acid. Specifically, it may be a form in which the lysine at positions 258, 260, 263, and 264 of SEQ ID NO: 74 is substituted by other amino acids. Specifically, the variant of IL-12B (p40) may include an amino acid sequence obtained by replacing at least one of the groups consisting of K258A, K260A, K263A, and K264A in the amino acid sequence of SEQ ID NO: 74. Specifically, the variant of IL-12B (p40) may include an amino acid sequence obtained by replacing K258A and K263A in the amino acid sequence of SEQ ID NO: 74, or may also include mutations of K260A and / or K264A in the amino acid sequence of SEQ ID NO: 74.

[0120] In one embodiment, the variant of IL-12B (p40) can be a form in which the arginine (R) or lysine (K) that binds to heparin in IL-12B is substituted by another amino acid. Specifically, it can be a form in which the 254th arginine and / or the 255th, 256th and 260th lysine of SEQ ID NO: 86 are substituted by other amino acids. Specifically, the variant of IL-12B (p40) may include an amino acid sequence obtained by replacing at least one selected from the group consisting of R254A, K255A, K256A and K260A in the amino acid sequence of SEQ ID NO: 86. Specifically, it may include mutations of R254A, K255A, K256A and K260A in the amino acid sequence of SEQ ID NO: 86.

[0121] In one embodiment, the variant of IL-12B(p40) may include the amino acid sequence of SEQ ID NO:77, SEQ ID NO:79, SEQ ID NO:89 or SEQ ID NO:91.

[0122] In one embodiment, the human IL-12B variant may consist of the following structural formula A:

[0123] [Structural Formula A]

[0124] X 1 -LX 2

[0125] Among them, X 1 is the amino acid sequence of SEQ ID NO:125,

[0126] X 2 is the amino acid sequence of SEQ ID NO: 126, and

[0127] L is VA 1 -A 2 -QA 3 -K * -A 4 -A 5 -A 6 -A 7 -K * -A 8 The amino acid sequence composed of.

[0128] A 1 R or Q, A 2 V, A or I, A 3 G or R, A 4 S, N or K * , A 5 K * , N or E, A 6 R or K, A 7 is E, M, or T, and A 8 K * or E.

[0129] At least one marked with * The amino acid residue in " may be substituted with a non-polar amino acid residue selected from the group consisting of A, G, I, L, M, F, P and V, but is not limited thereto.

[0130] In one embodiment, variants of IL-12B(p40) may include substitutions of amino acids involved in heparin binding to reduce the cytokine-related toxicity of IL-12 while maintaining the killing effect on cancer cells.

[0131] FAP and antigen binding site that specifically binds to FAP

[0132] The term "FAP (fibroblast activation protein)" as used herein refers to fibroblast activation protein, which is a protein expressed on the cell surface and presented in the environment of tumor cells of various tumor types or in tumor cells of various tumor types. It is known that FAP is selectively overexpressed on the surface of cancer-associated fibroblasts (CAFs) in the tumor microenvironment.

[0133] In addition, FAP is a homodimer containing two N-glycosylated subunits with an enzyme catalytic domain on its C-terminal extracellular domain, and the glycosylated form of FAP has both prolyl dipeptidyl peptidase and gelatinase activities.

[0134] On the other hand, FAP is a prolyl endopeptidase, which is a membrane-bound gelatinase of approximately 170 kDa. Prolyl endopeptidase FAP can recognize and cleave a specific amino acid sequence. Therefore, FAP is also called FAPα, seprase or circulating anti-plasma cleaving enzyme.

[0135] The amino acid sequence of FAP may be the amino acid sequence described in GenBank Accession No. AAC51668, and human FAP was first identified in cultured fibroblasts using monoclonal antibody (mAb) F19 (see International Patent Application Publication No. WO 93 / 05804). FAP is expressed in many cancers and is used as a promising antigen target for imaging, diagnosis, and treatment of various cancers due to its limited expression in normal tissues.

[0136] FAP includes any variants, isoforms and species homologs of human FAP, which are naturally expressed by cells or expressed on cells transfected with the FAP gene. The antibodies of the present invention can bind to FAP present on the membrane or cell surface of cancer cells (tumor cells or cells of tumor stroma) and may cause ADCC or other effector-mediated killing of cancer cells. In addition, it can be used to block the enzymatic activity of FAP (e.g., serine peptidase, gelatinase, collagenase activity), FAP-mediated ECM degradation, and FAP-mediated cell invasion or migration.

[0137] As used herein, the term "specific binding" refers to binding that is measurably different from non-specific interactions. Specific binding can be determined by competition with a control molecule similar to the target that has no binding activity.

[0138] As used herein, the term "antigen binding site (epitope)" refers to a determinant that interacts with a specific antigen binding site in an antibody variable region. An antigen binding site is a group of molecules, such as amino acids or sugar side chains, which generally have specific structural features as well as specific charge characteristics. An antigen binding site that specifically binds to FAP can be a general term for molecules that can specifically bind to an antigen antibody of FAP.

[0139] Furthermore, the antibody or fragment thereof may be used in any form as long as it contains an antigen-binding domain capable of specifically binding to FAP.

[0140] The antigen binding site may include other amino acids that are not directly involved in binding, or amino acids whose function is blocked by the amino acid residues in the antigen binding site.

[0141] In particular, the antigen binding site may be an antibody that specifically binds to FAP or a fragment thereof.

[0142] As used herein, the term "antibody" refers to a molecule containing an antigen binding site, and an immunologically active fragment of an immunoglobulin molecule containing an antigen binding site. The immunoglobulin molecule may be an immunoglobulin molecule of IgG, IgE, IgM, IgD, IgA, IgY, or a subclass thereof. Antibodies include synthetic antibodies, monoclonal antibodies, single domain antibodies, single chain antibodies, recombinantly produced antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, in vivo antibodies, scFv (including, for example, monospecific and bispecific, etc.), Fab fragments, F(ab') fragments, disulfide-linked Fv (sdFv), anti-idiotypic (anti-Id) antibodies, and antigen-binding fragments of antibodies, but are not limited thereto.

[0143] As used herein, the term "antibody fragment" may be a portion of an antibody, such as F(ab') 2 、F(ab) 2 , Fab', Fab, Fv, scFv. Regardless of the structure, antibody fragments bind to the same antigen recognized by the intact antibody.

[0144] In one embodiment, an antigen binding site that specifically binds to FAP may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 96, HCDR2 as shown in SEQ ID NO: 97, and HCDR3 as shown in SEQ ID NO: 98; and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 99, LCDR2 as shown in SEQ ID NO: 100, and LCDR3 as shown in SEQ ID NO: 101. Then, in one embodiment, an antigen binding site that specifically binds to FAP may have a heavy chain variable region as shown in SEQ ID NO: 102 and a light chain variable region as shown in SEQ ID NO: 103.

[0145] In addition, in one embodiment, the antigen binding site that specifically binds to FAP may include a heavy chain variable region of HCDR1 as shown in SEQ ID NO: 104, HCDR2 as shown in SEQ ID NO: 105, and HCDR3 as shown in SEQ ID NO: 106; and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 107, LCDR2 as shown in SEQ ID NO: 108, and LCDR3 as shown in SEQ ID NO: 109. Then, in one embodiment, the antigen binding site that specifically binds to FAP may have a heavy chain variable region as shown in SEQ ID NO: 110 and a light chain variable region as shown in SEQ ID NO: 111.

[0146] In one embodiment, the antigen binding site that specifically binds to FAP can be a scFv. Then, the scFv can include the heavy chain and light chain CDRs described above. In one embodiment, the scFv that specifically binds to FAP can have an amino acid sequence of SEQ ID NO: 72 or SEQ ID NO: 84.

[0147] In addition, the antigen binding site that specifically binds to FAP may include a known anti-FAP antibody or a fragment thereof. The anti-FAP antibody or a fragment thereof may refer to an antibody known to those skilled in the art, but is not limited thereto.

[0148] The anti-FAP antibody or fragment thereof may include at least one variable region selected from the group consisting of NG-641, AMG-506 / MP-0310, 28H1 of RG-7827, 4B9 of RG-7827, OMTX-705, 3F2, 4G8, 3D9, 4B3, 19G1, 20G8, 5B8, 5F1, 14B3, 16F1, 16F8, O3C9, 29B11, O2D7 and 23C10.

[0149] In another embodiment, as the antibody, an anti-FAP antibody or a fragment thereof disclosed in Korean Patent Application Publication No. KR20200037826A, U.S. Patent Application Publication No. US2020-0385488 A1, U.S. Patent No. US 3,924,445 B2, U.S. Patent No. US 9,011,847 B2, or U.S. Patent Application Publication No. US2017-007716 A1 can be used.

[0150] In one embodiment, the anti-FAP antibody may comprise the variable region of NG-641. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 127, HCDR2 as shown in SEQ ID NO: 128, and HCDR3 as shown in SEQ ID NO: 129, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 130, LCDR2 as shown in SEQ ID NO: 131, and LCDR3 as shown in SEQ ID NO: 132. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 248 and a light chain variable region as shown in SEQ ID NO: 249.

[0151] In one embodiment, the anti-FAP antibody may comprise the variable region of 28H1. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 133, HCDR2 as shown in SEQ ID NO: 134, and HCDR3 as shown in SEQ ID NO: 135, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 136, LCDR2 as shown in SEQ ID NO: 137, and LCDR3 as shown in SEQ ID NO: 138. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 250 and a light chain variable region as shown in SEQ ID NO: 251.

[0152] In one embodiment, the anti-FAP antibody may comprise the variable region of 4B9. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 139, HCDR2 as shown in SEQ ID NO: 140, and HCDR3 as shown in SEQ ID NO: 141, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 142, LCDR2 as shown in SEQ ID NO: 143, and LCDR3 as shown in SEQ ID NO: 144. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 252 and a light chain variable region as shown in SEQ ID NO: 253.

[0153] In one embodiment, the anti-FAP antibody may comprise the variable region of OMTX-705. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 145, HCDR2 as shown in SEQ ID NO: 146, and HCDR3 as shown in SEQ ID NO: 147, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 148, LCDR2 as shown in SEQ ID NO: 149, and LCDR3 as shown in SEQ ID NO: 150. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 254 and a light chain variable region as shown in SEQ ID NO: 255.

[0154] In one embodiment, the anti-FAP antibody may comprise the variable region of 3F2. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 151, HCDR2 as shown in SEQ ID NO: 152, and HCDR3 as shown in SEQ ID NO: 153, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 154, LCDR2 as shown in SEQ ID NO: 155, and LCDR3 as shown in SEQ ID NO: 156. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 256 and a light chain variable region as shown in SEQ ID NO: 257.

[0155] In one embodiment, the anti-FAP antibody may comprise the variable region of 4G8. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 157, HCDR2 as shown in SEQ ID NO: 158, and HCDR3 as shown in SEQ ID NO: 159, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 160, LCDR2 as shown in SEQ ID NO: 161, and LCDR3 as shown in SEQ ID NO: 162. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 258 and a light chain variable region as shown in SEQ ID NO: 259.

[0156] In one embodiment, the anti-FAP antibody may comprise the variable region of 3D9. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 163, HCDR2 as shown in SEQ ID NO: 164, and HCDR3 as shown in SEQ ID NO: 165, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 166, LCDR2 as shown in SEQ ID NO: 167, and LCDR3 as shown in SEQ ID NO: 168. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 260 and a light chain variable region as shown in SEQ ID NO: 261.

[0157] In one embodiment, the anti-FAP antibody may comprise the variable region of 4B3. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 169, HCDR2 as shown in SEQ ID NO: 170, and HCDR3 as shown in SEQ ID NO: 171, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 172, LCDR2 as shown in SEQ ID NO: 173, and LCDR3 as shown in SEQ ID NO: 174. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 262 and a light chain variable region as shown in SEQ ID NO: 263.

[0158] In one embodiment, the anti-FAP antibody may comprise the variable region of 19G1. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 175, HCDR2 as shown in SEQ ID NO: 176, and HCDR3 as shown in SEQ ID NO: 177, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 178, LCDR2 as shown in SEQ ID NO: 179, and LCDR3 as shown in SEQ ID NO: 180. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 264 and a light chain variable region as shown in SEQ ID NO: 265.

[0159] In one embodiment, the anti-FAP antibody may comprise the variable region of 20G8. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 181, HCDR2 as shown in SEQ ID NO: 182, and HCDR3 as shown in SEQ ID NO: 183, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 184, LCDR2 as shown in SEQ ID NO: 185, and LCDR3 as shown in SEQ ID NO: 186. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 266 and a light chain variable region as shown in SEQ ID NO: 267.

[0160] In one embodiment, the anti-FAP antibody may comprise the variable region of 5B8. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 187, HCDR2 as shown in SEQ ID NO: 188, and HCDR3 as shown in SEQ ID NO: 189, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 190, LCDR2 as shown in SEQ ID NO: 191, and LCDR3 as shown in SEQ ID NO: 192. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 268 and a light chain variable region as shown in SEQ ID NO: 269.

[0161] In one embodiment, the anti-FAP antibody may comprise the variable region of 5F1. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 193, HCDR2 as shown in SEQ ID NO: 194, and HCDR3 as shown in SEQ ID NO: 195, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 196, LCDR2 as shown in SEQ ID NO: 197, and LCDR3 as shown in SEQ ID NO: 198. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 270 and a light chain variable region as shown in SEQ ID NO: 271.

[0162] In one embodiment, the anti-FAP antibody may comprise the variable region of 14B3. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 199, HCDR2 as shown in SEQ ID NO: 200, and HCDR3 as shown in SEQ ID NO: 201, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 202, LCDR2 as shown in SEQ ID NO: 203, and LCDR3 as shown in SEQ ID NO: 204. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 272 and a light chain variable region as shown in SEQ ID NO: 273.

[0163] In one embodiment, the anti-FAP antibody may comprise the variable region of 16F1. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 205, HCDR2 as shown in SEQ ID NO: 206, and HCDR3 as shown in SEQ ID NO: 207, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 208, LCDR2 as shown in SEQ ID NO: 209, and LCDR3 as shown in SEQ ID NO: 210. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 274 and a light chain variable region as shown in SEQ ID NO: 275.

[0164] In one embodiment, the anti-FAP antibody may comprise the variable region of 16F8. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 211, HCDR2 as shown in SEQ ID NO: 212, and HCDR3 as shown in SEQ ID NO: 213, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 214, LCDR2 as shown in SEQ ID NO: 215, and LCDR3 as shown in SEQ ID NO: 216. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 276 and a light chain variable region as shown in SEQ ID NO: 277.

[0165] In one embodiment, the anti-FAP antibody may comprise the variable region of O3C9. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 217, HCDR2 as shown in SEQ ID NO: 218, and HCDR3 as shown in SEQ ID NO: 219, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 220, LCDR2 as shown in SEQ ID NO: 221, and LCDR3 as shown in SEQ ID NO: 222. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 278 and a light chain variable region as shown in SEQ ID NO: 279.

[0166] In one embodiment, the anti-FAP antibody may comprise the variable region of 22A3. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 223, HCDR2 as shown in SEQ ID NO: 224, and HCDR3 as shown in SEQ ID NO: 225, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 226, LCDR2 as shown in SEQ ID NO: 227, and LCDR3 as shown in SEQ ID NO: 228. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 280 and a light chain variable region as shown in SEQ ID NO: 281.

[0167] In one embodiment, the anti-FAP antibody may comprise the variable region of 29B11. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 229, HCDR2 as shown in SEQ ID NO: 230, and HCDR3 as shown in SEQ ID NO: 231, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 232, LCDR2 as shown in SEQ ID NO: 233, and LCDR3 as shown in SEQ ID NO: 234. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 282 and a light chain variable region as shown in SEQ ID NO: 283.

[0168] In one embodiment, the anti-FAP antibody may comprise the variable region of O2D7. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 235, HCDR2 as shown in SEQ ID NO: 236, and HCDR3 as shown in SEQ ID NO: 237, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 238, LCDR2 as shown in SEQ ID NO: 239, and LCDR3 as shown in SEQ ID NO: 240. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 284 and a light chain variable region as shown in SEQ ID NO: 285.

[0169] In one embodiment, the anti-FAP antibody may comprise the variable region of 23C10. Specifically, the antibody may include a heavy chain variable region comprising HCDR1 as shown in SEQ ID NO: 241, HCDR2 as shown in SEQ ID NO: 242, and HCDR3 as shown in SEQ ID NO: 243, and a light chain variable region comprising LCDR1 as shown in SEQ ID NO: 244, LCDR2 as shown in SEQ ID NO: 245, and LCDR3 as shown in SEQ ID NO: 246. In addition, the anti-FAP antibody may comprise a heavy chain variable region as shown in SEQ ID NO: 286 and a light chain variable region as shown in SEQ ID NO: 287.

[0170] In one embodiment, the anti-FAP antibody may be AMG-506 / MP-0310. Specifically, the antibody may include an amino acid sequence as shown in SEQ ID NO: 247.

[0171] The anti-FAP antibody specifically binds to FAP present on cancer cells, and any antibody can be used as long as it can induce cancer cell death.

[0172] The structure of the first monomer

[0173] The first monomer comprises IL-12 or a variant thereof.

[0174] The first monomer may also comprise an antigen binding site that specifically binds to FAP.

[0175] In one embodiment, the first monomer may comprise IL-12 or a variant thereof; and an Fc region fragment or a variant thereof.

[0176] In one embodiment, the first monomer may comprise IL-12 or a variant thereof, an Fc region fragment or a variant thereof, and an antigen binding site that specifically binds to FAP.

[0177] The first monomer may include the following structural formula (III) or (IV):

[0178] N'-X-[Linker (2)]p-Fc region fragment or variant thereof-[Linker (3)]q-(T)r-C'(III)

[0179] N'-(T)r-[Linker (2)]q-Fc region fragment or variant thereof-[Linker (3)]pX-C'(IV)

[0180] In structural formulas (III) and (IV),

[0181] N' can be the N terminus of the fusion protein,

[0182] C' can be the C-terminus of the fusion protein,

[0183] X can be structural formula (I) or (II),

[0184] T may be an antigen binding site that specifically binds to FAP,

[0185] Linkers (2) and (3) may be peptide linkers, and

[0186] p, q and r are each independently 0 or 1.

[0187] In one embodiment, when r is 0, the first monomer may be in the form of a fusion protein in which IL-12 or a variant thereof and an Fc region fragment or a variant thereof are linked via a peptide linker.

[0188] Then, the first monomer may include an amino acid sequence as shown in SEQ ID NO:3, as shown in SEQ ID NO:4, as shown in SEQ ID NO:5, as shown in SEQ ID NO:15, as shown in SEQ ID NO:20, as shown in SEQ ID NO:21, as shown in SEQ ID NO:22 or as shown in SEQ ID NO:32.

[0189] Then, in structural formula (III), when r is 1, the first monomer may be a form in which a monomer of an anti-FAP antibody is bound to IL-12 or a variant thereof.

[0190] Then, in structural formula (III), when r is 1, the first monomer may include an amino acid sequence as shown in SEQ ID NO:292, as shown in SEQ ID NO:293, as shown in SEQ ID NO:296, as shown in SEQ ID NO:297, as shown in SEQ ID NO:298, as shown in SEQ ID NO:299, as shown in SEQ ID NO:302 or as shown in SEQ ID NO:303.

[0191] Then, in structural formula (IV), when r is 1, the first monomer may include an amino acid sequence as shown in SEQ ID NO:294, as shown in SEQ ID NO:295, as shown in SEQ ID NO:300 or as shown in SEQ ID NO:301.

[0192] In one embodiment, when r is 1, the structural formula (III) may include the following structural formulas (III') and (III"):

[0193] N'-X-[Linker (2)]p-Fc region fragment or variant thereof-[Linker (3)]q-(T')-C'(III')

[0194] N'-(T")-C'(III")

[0195] In structural formulas (III') and (III"),

[0196] T' is the heavy chain region of an antibody that specifically binds to FAP, which includes the variable region and the CH1 region, or the light chain region of an antibody;

[0197] T" is the light chain region of an antibody that specifically binds to FAP, or the heavy chain region of an antibody, which includes a variable region and a CH1 region;

[0198] wherein T' and T" bind to each other to form a variable region of the antibody, wherein the variable region specifically binds to FAP;

[0199] Linkers (2) to (3) are peptide linkers,

[0200] p and q are each independently 0 or 1, and

[0201] N', X and C' are as defined above.

[0202] In one embodiment, when r is 1, the structural formula (IV) may include the following structural formulas (IV') and (IV"):

[0203] N'-(T')-[Linker (2)]q-Fc region fragment or variant thereof-[Linker (3)]pX-C'(IV'); and

[0204] N'-(T")-C'(IV")

[0205] In structural formulas (IV') and (IV"),

[0206] T' is the heavy chain region of an antibody that specifically binds to FAP, which includes the variable region and the CH1 region, or the light chain region of an antibody;

[0207] T" is the light chain region of an antibody that specifically binds to FAP, or the heavy chain region of an antibody, which includes a variable region and a CH1 region;

[0208] wherein T' and T" bind to each other to form a variable region of the antibody, wherein the variable region specifically binds to FAP;

[0209] Linkers (2) to (3) are peptide linkers,

[0210] p and q are each independently 0 or 1, and

[0211] N', X and C' are as defined above.

[0212] Then, the first monomer can include an amino acid sequence as shown in SEQ ID NO:10 and SEQ ID NO:2; as shown in SEQ ID NO:11 and SEQ ID NO:2; as shown in SEQ ID NO:27 and SEQ ID NO:19; as shown in SEQ ID NO:28 and SEQ ID NO:19; as shown in SEQ ID NO:294 and SEQ ID NO:2; as shown in SEQ ID NO:295 and SEQ ID NO:2; as shown in SEQID NO:300 and SEQ ID NO:19; or as shown in SEQ ID NO:301 and SEQ ID NO:19.

[0213] The structure of the second monomer

[0214] The second monomer may also comprise an antigen binding site that specifically binds to FAP.

[0215] In one embodiment, the second monomer may comprise a first FAP binding site and a second FAP binding site.

[0216] The antigen binding site that specifically binds to FAP may be Fab, scFv, Fv or a fragment thereof. Then, the first FAP binding site may be Fab, and the second FAP binding site may be Fv or scFv.

[0217] The second FAP binding site can be bound to the N-terminus or C-terminus of the second monomer. Specifically, the second monomer can be additionally bound to the C-terminus of the heavy chain, the C-terminus of the light chain, or the C-terminus of the variable region.

[0218] The second monomer may include the following structural formula (V):

[0219] N'-(R)s-[Linker (4)]tQ-[Linker (5)]u-Fc region fragment or variant thereof-[Linker (6)]v-(W)a-C'(V)

[0220] In structural formula (V),

[0221] N' can be the N terminus of the fusion protein,

[0222] C' can be the C-terminus of the fusion protein,

[0223] R and Q may be antigen binding sites that specifically bind to FAP,

[0224] W may be a scFv that specifically binds to FAP; or IL-12 of structural formula (I) or (II) or a variant thereof,

[0225] Linkers (4), (5) and (6) may each be a peptide linker, and

[0226] s, t, u, v and a can each independently be 0 or 1.

[0227] In one embodiment, structural formula (V) may include at least one selected from the group consisting of amino acid sequences shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 31, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 300 and SEQ ID NO: 301.

[0228] In one embodiment, structural formula (V) may include the following structural formulas (V') and (V"):

[0229] N'-(R')s-[Linker (4)]t-Q'-[Linker (5)]u-Fc region fragment or variant thereof-[Linker (6)]p-(W)a-C'(V')

[0230] N'-(R")s-[Linker (4)]tQ"-[Linker (7)]x-(W)b-C'(V")

[0231] In structural formulas (V') and (V"),

[0232] R' can be a heavy chain region of an antibody that specifically binds to FAP, which includes a variable region and a CH1 region, or a light chain region of an antibody;

[0233] R" can be a light chain region of an antibody that specifically binds to FAP, or a heavy chain region of an antibody, which includes a variable region and a CH1 region;

[0234] Wherein, R' and R" can bind to each other to form a variable region of an antibody, wherein the variable region specifically binds to FAP;

[0235] Q' can be a heavy chain region of an antibody that specifically binds to FAP, which includes a variable region and a CH1 region, or a light chain region of an antibody;

[0236] Q" may be a light chain region of an antibody that specifically binds to FAP, or a heavy chain region of an antibody, which includes a variable region and a CH1 region;

[0237] Wherein, Q' and Q" can combine with each other to form a variable region of an antibody, wherein the variable region specifically binds to FAP,

[0238] W may be a scFv that specifically binds to FAP; or IL-12 of structural formula (I) or (II) or a variant thereof,

[0239] Linkers (4), (5), (6) and (7) may each be a peptide linker, and

[0240] s, t, u, x, a and b may each independently be 0 or 1.

[0241] In one embodiment, structural formula (V') can be SEQ ID NO:1, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:14, SEQ ID NO:18, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:300 or SEQ ID NO:301.

[0242] In one embodiment, structural formula (V") can be SEQ ID NO:2, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:19, SEQ ID NO:24 or SEQ ID NO:26.

[0243] In one embodiment, the second monomer may include a heavy chain consisting of the amino acid sequence of SEQ ID NO:102 and a light chain consisting of the amino acid sequence of SEQ ID NO:103; or a heavy chain consisting of the amino acid sequence of SEQ ID NO:110 and a light chain consisting of the amino acid sequence of SEQ ID NO:111.

[0244] Furthermore, when W is scFv, W may have the amino acid sequence of SEQ ID NO: 72 or SEQ ID NO: 84.

[0245] Peptide linker

[0246] As used herein, the term "peptide linker" refers to a peptide used to provide a physical and chemical distance or connect fusion protein domains. The linker may comprise a hinge region of an immunoglobulin.

[0247] Peptide linkers (1) to (7) refer to peptide linkers composed of amino acids. Specifically, peptide linkers (2) or (5) may be composed of 5 to 80 consecutive amino acids, 7 to 70 consecutive amino acids, or 10 to 60 consecutive amino acids, or 12 to 50 amino acids. Peptide linkers may include (G 4 S)n (where n is an integer from 1 to 10). Then, in (G 4In S)n, n can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 respectively.

[0248] In one embodiment, the peptide linker (1) may be a peptide linker consisting of an amino acid sequence as shown in SEQ ID NO:93, SEQ ID NO:94 or SEQ ID NO:95.

[0249] The peptide linker (2) or (5) may consist of 5 to 80 consecutive amino acids, 7 to 70 consecutive amino acids, 10 to 60 consecutive amino acids, or 12 to 50 amino acids. In one embodiment, the peptide linker (2) may consist of 30 amino acids. In addition, the peptide linker (2) may contain at least one cysteine. Specifically, it may contain one, two or three cysteines. In addition, the peptide linker (2) may be derived from the hinge of an immunoglobulin, and may further include (G 4 S)n (wherein n is an integer from 1 to 10). Specifically, the peptide linker (2) may comprise a hinge region consisting of any one of the following amino acid sequences: SEQ ID NO: 112, SEQ ID NO: 113, SEQ ID NO: 114, SEQ ID NO: 115, SEQ ID NO: 116, SEQ ID NO: 117 and SEQ ID NO: 119.

[0250] In addition, the peptide linkers (3), (4), (6) and (7) may consist of 1 to 30 consecutive amino acids, 5 to 20 consecutive amino acids or 10 to 15 consecutive amino acids. 4 S)n (where n is an integer from 1 to 10). Then, in (G 4 In S)n, n can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 respectively.

[0251] Furthermore, specifically, the peptide linker (2), (3) or (5) may include SEQ ID NO:93 or SEQ ID NO:94.

[0252] In one embodiment of the present invention, the peptide linker (2) or (5) may be a peptide linker comprising an amino acid sequence as shown in SEQ ID NO:118 or SEQ ID NO:120.

[0253] Fc region and its fragments

[0254] Then, the immunoglobulin fragment can be an Fc region of an immunoglobulin. The Fc region of an immunoglobulin can be a wild-type Fc domain and an Fc domain variant. Then, the Fc region can be the Fc region of IgG, IgA, IgE, IgD or IgM. Specifically, it may be derived from IgG1 or IgG2a.

[0255] As used herein, the term "Fc domain variant" may refer to a form that is different from the wild-type Fc domain in terms of glycosylation pattern, has high glycosylation compared to the wild-type Fc domain, has low glycosylation compared to the wild-type Fc domain, or has a deglycosylated form. In addition, glycosylated Fc domains are also included. The Fc domain or its variant may be adapted to have an adjusted amount of sialic acid, fucosylation, or glycosylation by culture conditions or genetic manipulation of the host.

[0256] In addition, the glycosylation of the Fc domain of the immunoglobulin can be modified by conventional methods, such as chemical methods, enzyme methods, and genetic engineering methods using microorganisms. In addition, the Fc domain variant can be a mixed form of the respective Fc regions of immunoglobulins IgG, IgA, IgE, IgD or IgM. In addition, the Fc domain variant can be a form in which certain amino acids in the Fc domain are substituted by other amino acids.

[0257] The "amino acid" introduced by substitution and / or addition can be any one selected from the group consisting of lysine (K), alanine (A), arginine (R), asparagine (N), aspartic acid (D), cysteine ​​(C), glutamine (Q), glutamic acid (E), glycine (G), histidine (H), isoleucine (I), leucine (L), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y) and valine (V).

[0258] Furthermore, the Fc region may comprise a knob structure or a hole structure.

[0259] As used herein, the term "knob-in-hole" is a design strategy for making antibodies that specifically bind to different regions, such as bispecific antibodies, multispecific antibodies, or heterodimeric antibodies. Knob-in-hole is also called knob-in-hole. Generally, the technology involves introducing a knob at the interface of a first polypeptide (e.g., the first CH3 domain of a first antibody heavy chain) and introducing a corresponding hole at the interface of a second polypeptide (e.g., the second CH3 domain of a second antibody heavy chain), so that the knob can be positioned in the hole to promote the formation of heterodimers and hinder the formation of homodimers.

[0260] A "knob" is constructed by replacing small amino acid side chains at the interface of a first polypeptide (e.g., the first CH3 domain of a first antibody heavy chain) with larger side chains (e.g., arginine, phenylalanine, tyrosine, or tryptophan). A complementary "hole" of the same or similar size is created in the knob by replacing large amino acid side chains at the interface of a second polypeptide (e.g., the second CH3 domain of a second antibody heavy chain) with smaller side chains (e.g., alanine, serine, valine, or threonine). Knobs and holes can be created by altering nucleic acids encoding polypeptides, such as by site-specific mutagenesis or by peptide synthesis.

[0261] In one embodiment, the knob structure of IgG1 may be SEQ ID NO: 13 or SEQ ID NO: 288, and the pore structure may be SEQ ID NO: 12 or SEQ ID NO: 289. The knob structure or the pore structure may be a form in which amino acids 146, 148, and 187 are substituted with other amino acids. Specifically, in one embodiment of the present invention, the knob structure or the pore structure may be a form in which one or more selected from the group consisting of T146W, T146S, L148A, and Y187V are substituted. Specifically, the knob structure may be a form substituted with T146W, and the pore structure may be a form substituted with T146S, L148A, and Y187V.

[0262] On the other hand, in one embodiment of the present invention, the knob structure of IgG2a may be SEQ ID NO: 30 or SEQ ID NO: 290, and the hole structure may be SEQ ID NO: 29 or SEQ ID NO: 291. The knob structure or the hole structure may be a form in which the amino acids 152, 154, and 193 of the amino acid sequence of SEQ ID NO: 305 are substituted with other amino acids. Specifically, in one embodiment of the present invention, the knob structure or the hole structure may be a form in which the amino acid sequence of SEQ ID NO: 305 is substituted with T152W or T152S, M154A, and Y193V. Specifically, the knob structure may be a form substituted with T152W, and the hole structure may be a form substituted with T152S, M154A, and Y193V.

[0263] In one embodiment, the Fc domain variant may include a DANG mutation or a NG mutation. Then, "DANG mutation" refers to the D265A / N297G mutation used to remove effector function in human IgG1 or mouse IgG2a.

[0264] Effector functions mediated by the Fc region in IgG molecules include C1q binding, complement-dependent cytotoxicity, Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis, downregulation of cell surface receptors (e.g., B cell receptor, BCR), etc. Generally, these effector functions require the Fc region to bind to a binding domain (e.g., an antibody variable domain).

[0265] The effector function can be altered by replacing the amino acid sequence of the non-mutated Fc region, and the Fc region that changes the effector function can be designed, for example, by modifying C1q binding and / or FcR binding, thereby changing the CDC activity and / or ADCC activity. In other words, the "DANG mutation" means that the effector function mediated by the Fc region is removed from the IgG molecule, so that the unwanted effector function does not occur during the antibody production process.

[0266] In one embodiment, the DANG mutation may be in the form of amino acids in human IgG1 of SEQ ID NO: 289 being substituted by D45A / N77G. In addition, it may be in the form of amino acids in mouse IgG2a of SEQ ID NO: 291 being substituted by D51A / N83G.

[0267] Structure of fusion protein

[0268] The fusion protein may be an antibody. Specifically, the antibody may be a heterodimeric antibody comprising a knob structure within the pore.

[0269] The fusion protein may include structural formula (III) and structural formula (V); or structural formula (IV) and structural formula (V).

[0270] More specifically, one embodiment of the fusion protein may include the following first monomer (i) or (ii); and the following second monomer (iii), (iv), (v) or (vi):

[0271] Examples of first monomers:

[0272] (i) When r is 0, the structural formula (III)

[0273] (ii) When r is 1, the structural formula (IV)

[0274] Examples of the second monomer:

[0275] (iii) When s, a and b are 0, the structural formula (V') and the structural formula (V") are

[0276] (iv) When s is 1 and a and b are 0, the structural formula (V') and the structural formula (V") are

[0277] (v) When s and b are 0 and a is 1, the structural formula (V') and the structural formula (V")

[0278] (vi) When b is 1 and s and a are 0, structural formula (V') and structural formula (V").

[0279] In one embodiment, the fusion protein may include a first monomer comprising the above (i); and a second monomer comprising the above (iii) (the first from the left in Figure 35). Then, the fusion protein may include at least one amino acid sequence selected from the following group: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22. Specifically, the fusion protein may include SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3; SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 4; SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 5; SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20; SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 21; or SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 22.

[0280] In one embodiment, the fusion protein may include a first monomer comprising the above (i); and a second monomer comprising the above (iv) (second from the left in FIG. 35 ). Then, the fusion protein may include at least one amino acid sequence selected from the following group: SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 20, SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24. Specifically, the fusion protein may include SEQ ID NO: 3, SEQ ID NO: 6, and SEQ ID NO: 7; SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7; SEQ ID NO: 20, SEQ ID NO: 23, and SEQ ID NO: 24; or SEQ ID NO: 22, SEQ ID NO: 23, and SEQ ID NO: 24.

[0281] In one embodiment, the fusion protein may include a first monomer comprising the above (i); and a second monomer comprising the above (v) (third from the left in FIG. 35 ). Then, the fusion protein may include at least one amino acid sequence selected from the following group: SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 8, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 25. Specifically, the fusion protein may include SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 8; SEQ ID NO: 2, SEQ ID NO: 5, and SEQ ID NO: 8; SEQ ID NO: 19, SEQ ID NO: 20, and SEQ ID NO: 25; or SEQ ID NO: 19, SEQ ID NO: 22, and SEQ ID NO: 25.

[0282] In one embodiment, the fusion protein may include a first monomer comprising the above (i); and a second monomer comprising the above (vi) (the fourth from the left in FIG. 35 ). Then, the fusion protein may include at least one amino acid sequence selected from the following group: SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 18, SEQ ID NO: 20, SEQ ID NO: 22, and SEQ ID NO: 26. Specifically, the fusion protein may include SEQ ID NO: 1, SEQ ID NO: 3, and SEQ ID NO: 9; SEQ ID NO: 1, SEQ ID NO: 5, and SEQ ID NO: 9; SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 26; or SEQ ID NO: 18, SEQ ID NO: 22, and SEQ ID NO: 26.

[0283] In one embodiment, the fusion protein may include a first monomer comprising the above (ii); and a second monomer comprising the above (iii) (the fifth from the left in FIG. 35 ). Then, the fusion protein may include at least one amino acid sequence selected from the following group: SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 27, and SEQ ID NO: 28. Specifically, the fusion protein may include SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 10; SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 11; SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 27; or SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 28.

[0284] In addition, in one embodiment, the fusion protein dimer comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP can be a fusion protein dimer comprising a monomer of structural formula (III) and a monomer of structural formula (V) (Figure 36 left). Then, in structural formula (III), r is 1, and in structural formula (V), s, a, and t are 0. Then, structural formula (V) may include (V') and (V"). Then, in (V') and (V"), s, a, t, and b are 0. In addition, the Fc region of the dimer has a knob structure in the hole, through which different fusion proteins can bind to each other.

[0285] Specifically, the fusion protein may include at least one amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 292, SEQ ID NO: 293, SEQ ID NO: 298, and SEQ ID NO: 299. Specifically, the fusion protein may include SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 292; SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 293; SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 298; or SEQ ID NO: 18, SEQ ID NO: 19, and SEQ ID NO: 299.

[0286] In addition, the fusion protein dimer comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP can be a fusion protein dimer including structural formula (V) (middle in Figure 36). Then, the fusion protein dimer can include (V') and (V"). Then, in structural formula (V), s and t are 0, and a is 1. In addition, in (V') and (V"), s, t and b are 0, and a is 1. In addition, the fusion protein dimer can be a fusion protein dimer including structural formula (IV). Then, in structural formula (IV), r is 1.

[0287] Specifically, the fusion protein may include at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 19, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 300, and SEQ ID NO: 301. Specifically, the fusion protein may include SEQ ID NO: 2 and SEQ ID NO: 294; SEQ ID NO: 2 and SEQ ID NO: 295; SEQ ID NO: 19 and SEQ ID NO: 300; or SEQ ID NO: 19 and SEQ ID NO: 301.

[0288] In one embodiment, the fusion protein dimer comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP may be a fusion protein dimer comprising structural formula (III) (right side in FIG. 36 ). Then, in structural formula (III), r is 1.

[0289] Specifically, the fusion protein may include SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:302 or SEQ ID NO:303.

[0290] The multi-specific fusion proteins herein can be in a chemically modified form. In one embodiment, the fusion protein can be chemically modified by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization with known protection / blocking groups, proteolytic cleavage, and / or binding to cellular ligands or other proteins. Many of these chemical modifications can be performed by known techniques.

[0291] Polynucleotide encoding fusion protein

[0292] In another aspect of the present invention, a polynucleotide encoding the first monomer or a polynucleotide encoding the second monomer is provided.

[0293] In one embodiment, the polypeptide of the first monomer may include SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:15, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:292, SEQ ID NO:293, SEQ ID NO:294, SEQ ID NO:295, SEQ ID NO:296, SEQ ID NO:297, SEQ ID NO:298, SEQ ID NO:299, SEQ ID NO:300, SEQ ID NO:301, SEQ ID NO:302, or SEQ ID NO:303. NO:303 has an amino acid sequence that is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identical.

[0294] In one embodiment, the polynucleotide encoding the first monomer can be at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identical to SEQ ID NO:38, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:50, SEQ ID NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:62, SEQ ID NO:63, or SEQ ID NO:67.

[0295] In one embodiment, the polypeptide of the second monomer may comprise a polypeptide having the same or similar structure as SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 14, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 31, SEQ ID NO: 294, SEQ ID NO: 295, SEQ ID NO: 300, or SEQ ID NO: NO:301 has an amino acid sequence with about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identity.

[0296] In one embodiment, the polynucleotide encoding the second monomer can be at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 86%, at least about 87%, at least about 88%, at least about 89%, at least about 90%, at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or at least about 100% identical to SEQ ID NO:36, SEQ ID NO:37, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:49, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:58, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:66, or SEQ ID NO:306.

[0297] The polynucleotide may also include a nucleic acid encoding a signal sequence or leader sequence. As used herein, the term "signal sequence" refers to a signal peptide that directs secretion of a target protein. The signal peptide is translated and then cleaved in the host cell. Specifically, the signal sequence is an amino acid sequence that initiates protein transport through the endoplasmic reticulum (ER) membrane.

[0298] Signal sequences are well known in the art for their properties. Such signal sequences typically contain 16 to 30 amino acid residues, and may contain more or less than this amount. A typical signal peptide consists of three regions, a basic N-terminal region, a central hydrophobic region, and a more polar C-terminal region. The central hydrophobic region contains 4 to 12 hydrophobic residues that cause the signal sequence to be fixed during transport of the immature polypeptide through the membrane lipid bilayer.

[0299] After initiation, the signal sequence is cut by a cellular enzyme (commonly referred to as a signal peptidase) in the lumen of the ER. Then, the signal sequence may be a secretory signal sequence of tPa (tissue plasminogen activator), HSV gDs (signal sequence of herpes simplex virus glycoprotein D) or growth hormone. Preferably, a secretory signal sequence for higher eukaryotic cells including mammals etc. may be used. In addition, a wild-type signal sequence may be used, or a signal sequence substituted by a codon having a high expression frequency in a host cell may be used.

[0300] Use of a pharmaceutical composition comprising a fusion protein and an anticancer agent

[0301] The composition comprising a fusion protein comprising IL-12 or a variant thereof and an antigen binding site that specifically binds to FAP and an anticancer agent as an active ingredient of the present invention can be used to treat or prevent cancer and / or can increase the efficacy of treatment.

[0302] Therefore, the present invention can provide the use of fusion protein for treating cancer. In addition, the use can be used in combination with anticancer agents for treating cancer. In addition, the present invention provides the use of fusion protein for preparing a drug for treating cancer in combination with an anticancer agent.

[0303] The fusion proteins and fusion protein dimers are as described above.

[0304] Then, the cancer can be any one selected from the group consisting of gastric cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, skin cancer, bone cancer, multiple myeloma, glioma, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, chronic lymphocytic leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer and lymphoma.

[0305] The preferred dosage of the pharmaceutical composition varies according to the patient's condition and weight, the severity of the disease, the drug form, the route of administration and the duration, and can be appropriately selected by those skilled in the art. In the pharmaceutical composition for treating or preventing tumors of the present invention, the active ingredient can be contained in any amount (effective amount) according to the application, dosage form, mixing purpose, etc., as long as the active ingredient can show the activity of treating tumors or, in particular, the therapeutic effect on cancer. Its conventional effective amount will be determined in the range of 0.001% to 20.0% by weight based on the total weight of the composition. Then, the term "effective amount" refers to the amount of the active ingredient, which is able to induce the effect of improving or treating the disease condition, in particular, inducing the effect of improving or treating the cancer condition. This effective amount can be determined experimentally within the known range of those skilled in the art.

[0306] As used herein, the term "treatment" may be used to refer to both therapeutic and prophylactic treatment. Prevention, however, may be used to refer to alleviation or reduction of a subject's pathological condition or disease. In one embodiment, the term "treatment" includes both application or any form of administration, and also includes use for the treatment of a disease in a mammal (including a human). In addition, the term includes inhibiting or slowing the progression of a disease; and includes restoring or repairing impaired or lost functions to partially or completely alleviate the disease; stimulating inefficient processes; or alleviating a serious disease.

[0307] As used herein, the term "efficacy" can be determined by one or more parameters, such as survival rate over a certain period of time, such as 1 year, 5 years or 10 years, or disease-free survival rate. In addition, the parameters may include the inhibition of the size of at least one tumor in the individual.

[0308] Pharmacokinetic parameters (e.g., bioavailability) and basal parameters (e.g., clearance) may also affect efficacy. Thus, "enhanced efficacy" (e.g., improvement in efficacy) may be due to enhanced pharmacokinetic parameters and enhanced efficacy, which can be measured by comparing tumors in experimental animals or human subjects, parameters such as clearance and treatment or improvement.

[0309] As used herein, the term "therapeutically effective amount" or "pharmaceutically effective amount" refers to an amount of a compound or composition that is effective in preventing or treating the disease in question, which is sufficient to treat the disease at a reasonable benefit / risk ratio applicable to medical treatment and does not cause side effects. The level of the effective amount can be determined depending on factors including the patient's health status, the type and severity of the disease, the activity of the drug, the patient's sensitivity to the drug, the mode of administration, the time of administration, the route of administration and the excretion rate, the duration of treatment, the formulation or concurrently used drugs, and other factors known in the medical field. In one embodiment, a therapeutically effective amount refers to an amount of a drug that is effective in treating cancer.

[0310] Then, the pharmaceutical composition may further comprise a pharmaceutically acceptable carrier. A pharmaceutically acceptable carrier may be any carrier, as long as the carrier is a non-toxic substance suitable for delivery to a patient. Distilled water, alcohol, fat, wax and inert solids may be contained as carriers. Pharmaceutically acceptable adjuvants (buffers, dispersants) may also be included in the pharmaceutical composition.

[0311] Specifically, by including a pharmaceutically acceptable carrier in addition to the active ingredient, the pharmaceutical composition can be prepared into a parenteral preparation according to the route of administration using conventional methods known in the art. Then, the term "pharmaceutically acceptable" means that the carrier does not have greater toxicity than the toxicity that the subject to be administered (prescribed) can adapt to, while not inhibiting the activity of the active ingredient.

[0312] When the pharmaceutical composition is prepared as a parenteral preparation, it can be prepared into a preparation in the form of an injection, a transdermal patch, a nasal inhalation or a suppository with a suitable carrier according to methods known in the art. In the case of being prepared as an injection, sterile water, ethanol, a polyol such as glycerol or propylene glycol, or a mixture thereof can be used as a suitable carrier; isotonic solutions such as Ringer's solution, phosphate buffered saline (PBS) containing triethanolamine or sterile water for injection, and 5% glucose, etc. can be preferably used. The formulation of the pharmaceutical composition is known in the art, and specific reference can be made to Remington's Pharmaceutical Science (19th edition, 1995) and the like. This document is considered to be part of this specification.

[0313] The preferred dosage range of the pharmaceutical composition can be 0.01 μg / kg to 10 g / kg per day, or 0.01 mg / kg to 1 g / kg, depending on the patient's condition, body weight, sex, age, severity of the patient and route of administration. The dosage can be administered once a day or divided into several times a day. Such dosage should not be construed as limiting the scope of the present invention in any aspect.

[0314] The subjects to which the pharmaceutical composition can be applied (prescribed) are mammals and humans, and humans are particularly preferred. In addition to the active ingredient, the pharmaceutical composition of the present application may also contain any compound or natural extract that is known to have a therapeutic effect on tumors.

[0315] Combination therapy comprising fusion proteins and anticancer agents

[0316] In another aspect of the present invention, a method for treating or preventing cancer is provided, comprising administering to a subject a fusion protein or a dimer thereof, wherein the fusion protein comprises a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP; and an anticancer agent.

[0317] Then, the subject may be a subject suffering from cancer. In addition, the subject may be a mammal, preferably a human. The fusion protein or its dimer, and the anticancer agent are as described above.

[0318] The route of administration, dosage and frequency of administration of the fusion protein or fusion protein dimer can be changed according to the patient's condition and whether there is a side effect, so the fusion protein or fusion protein dimer can be administered to the subject in various ways and amounts. The best administration method, dosage and frequency of administration can be selected by those skilled in the art within an appropriate range. In addition, the fusion protein or fusion protein dimer can be administered in combination with other drugs or physiologically active substances (e.g., anticancer agents), and its therapeutic effect is known relative to the disease to be treated, or it can be formulated into the form of a combined preparation with other drugs.

[0319] Hereinafter, the present invention will be described in more detail by the following examples. However, the following examples are only used to illustrate the present invention, and the protection scope of the present invention is not limited thereto.

[0320] Preparation Example 1. Overview of human fusion protein anti-FAP / IL-12 IgG1 DANG

[0321] [Table 1]

[0322]

[0323]

[0324] [seq1] consists of a human anti-FAP heavy chain variable region sequence and a human IgG1 Fc, in which the effector function is removed by the DANG mutation (D265A, N297G) and the knob structure is formed by the T366W mutation.

[0325] [seq2] consists of the human anti-FAP light chain sequence.

[0326] [seq3] consists of the human IL-12p40 (β) region sequence and the linker GGGGSGGGGSGGGGS, the human interleukin 12p35 (α) region sequence, the linker GGGGSGGGGS and human IgG1 Fc, in which the effector function is removed by DANG mutation (D265A, N297G), and the pore structure is formed by T366S, L368A and Y407V mutations.

[0327] [seq4] consists of a sequence in which the lysine (K) at amino acids 280 and 285 that bind to heparin in the human IL-12p40 (β) region are mutated to alanine (A), the linker GGGGSGGGGSGGGGS, the sequence of the human IL-12p35 (α) region, the linker GGGGSGGGGS, and the human IgG1 Fc pore DANG.

[0328] [seq5] consists of a sequence in which the lysine (K) at amino acids 280, 282, 285, and 286 in the human IL-12p40 (β) region that binds to heparin are mutated to alanine (A), the linker GGGGSGGGGSGGGGS, the sequence of the human IL-12p35 (α) region, the linker GGGGSGGGGS, and the human IgG1 Fc pore DANG.

[0329] [seq6] consists of the human anti-FAP heavy chain variable region sequence, the linker GGGGSGGGGSGGGGS, the human anti-FAP heavy chain variable region sequence and the human IgG1 Fc knob DANG.

[0330] [seq7] consists of the human anti-FAP light chain variable region sequence, the linker GGGGSGGGGSGGGGS and the human anti-FAP light chain sequence.

[0331] [seq8] consists of the human anti-FAP heavy chain variable region sequence, the human IgG1 Fc knob DANG, the linker GGGGSGGGGSGGGGS, the human anti-FAP heavy chain variable region sequence, the linker GGGGSGGGGSGGGGSGGGGS and the human anti-FAP light chain variable region sequence.

[0332] [seq9] consists of a human anti-FAP light chain sequence, a linker GGGGSGGGGSGGGGS, a human anti-FAP heavy chain variable region sequence, a linker GGGGSGGGGSGGGGSGGGGS and a human anti-FAP light chain variable region sequence.

[0333] [seq10] consists of the human anti-FAP heavy chain sequence, the human IgG1 Fc pore DANG, the linker GGGGSGGGGSGGGGS, the p40(β) region sequence of human IL-12, the linker GGGGSGGGGSGGGGS and the human IL-12 p35(α) region sequence.

[0334] [seq11] consists of the human anti-FAP heavy chain sequence, the human IgG1 Fc pore DANG, the linker GGGGSGGGGSGGGGS, the p40(β) region sequence of human IL-12 containing four amino acid mutations involved in heparin binding, the linker GGGGSGGGGSGGGGS and the human IL-12 p35(α) region sequence.

[0335] [seq12] consists only of human IgG1 Fc pore DANG.

[0336] [seq13] consists only of the human IgG1 Fc knob DANG.

[0337] [seq14] consists of the human anti-FAP heavy chain variable region sequence and human IgG1 Fc DANG.

[0338] [seq15] consists of the p40(β) region sequence of human IL-12 containing four amino acid mutations involved in heparin binding, the linker GGGGSGGGGSGGGGS, the human IL-12 p35(α) region sequence, the linker GGGGSGGGGS and human IgG1 Fc DANG.

[0339] [seq16] consists of the heavy chain sequence of human anti-CD20 antibody and human IgG1 Fc knob DANG.

[0340] [seq17] is the light chain sequence of human anti-CD20 antibody.

[0341] [seq292] consists of human IL-12p40 (β) region sequence, linker GGGGSGGGGSGGGGS, human IL-12p35 (α) region sequence, linker GGGGSGGGGS and human IgG1 Fc pore DANG, linker GGGGSGGGGSGGGGS, human anti-FAP heavy chain variable region sequence, linker GGGGSGGGGSGGGGSGGGGS and human anti-FAP light chain variable region sequence.

[0342] [seq293] consists of a human IL-12p40 (β) region sequence comprising four amino acid mutations involved in heparin binding, a linker GGGGSGGGGSGGGGS, a human IL-12p35 (α) region sequence, a linker GGGGSGGGGS and a human IgG1 Fc pore DANG, a linker GGGGSGGGGSGGGGS, a human anti-FAP heavy chain variable region sequence, a linker GGGGSGGGGSGGGGSGGGGS and a human anti-FAP light chain variable region sequence.

[0343] [seq294] consists of the human anti-FAP heavy chain sequence, human IgG1 Fc DANG, the linker GGGGSGGGGSGGGGS, the p40(β) region sequence of human IL-12, the linker GGGGSGGGGSGGGGS and the human IL-12 p35(α) region sequence.

[0344] [seq295] consists of the human anti-FAP heavy chain sequence, human IgG1 Fc DANG, the linker GGGGSGGGGSGGGGS, the p40(β) region sequence of human IL-12 containing four amino acid mutations involved in heparin binding, the linker GGGGSGGGGSGGGGS and the human IL-12 p35(α) region sequence.

[0345] [seq296] consists of human IL-12p40 (β) region sequence, linker GGGGSGGGGSGGGGS, human IL-12p35 (α) region sequence, linker GGGGSGGGGS and human IgG1 Fc DANG, linker GGGGSGGGGSGGGGS, human anti-FAP heavy chain variable region sequence, linker GGGGSGGGGSGGGGSGGGGS and human anti-FAP light chain variable region sequence.

[0346] [seq297] consists of a human IL-12p40 (β) region sequence comprising four amino acid mutations involved in heparin binding, a linker GGGGSGGGGSGGGGS, a human IL-12p35 (α) region sequence, a linker GGGGSGGGGS and human IgG1 Fc DANG, a linker GGGGSGGGGSGGGGS, a human anti-FAP heavy chain variable region sequence, a linker GGGGSGGGGSGGGGSGGGGS and a human anti-FAP light chain variable region sequence.

[0347] T1.01 (seq1, seq2, seq3) is a bispecific antibody in which the human anti-FAP sequence targeting human FAP and the human IL-12 sequence form a knob-in-the-hole structure and remove the effector function.

[0348] T1.02 (seq1, seq2, seq4) is a bispecific antibody in which a human anti-FAP sequence targeting human FAP and a human IL-12 sequence containing two amino acid mutations involved in heparin binding form a knob-in-hole structure and remove effector function.

[0349] T1.03 (seq1, seq2, seq5) is a bispecific antibody in which a human anti-FAP sequence targeting human FAP and a human IL-12 sequence containing four amino acid mutations involved in heparin binding form a knob-in-hole structure and remove effector function.

[0350] T1.04 (seq3, seq6, seq7) is a bispecific antibody in which the human anti-FAP sequence and the human IL-12 sequence in the form of a dual variable domain immunoglobulin (DVD-Ig) form a knob-in-the-hole structure and remove the effector function.

[0351] T1.05 (seq5, seq6, seq7) is a bispecific antibody in which the human anti-FAP sequence in DVD-Ig format and the human IL-12 sequence containing amino acid mutations (four) involved in heparin binding form a knob-in-hole structure and remove the effector function.

[0352] T1.06 (seq2, seq3, seq8) is a bispecific antibody in which a single-chain variable fragment of the human anti-FAP sequence (scFv of the human anti-FAP sequence targeting human FAP) is connected to the C-terminus of the heavy chain, the human IL-12 sequence forms a knob-in-the-hole structure, and the effector function is removed.

[0353] T1.07 (seq2, seq5, seq8) is a bispecific antibody in which a scFv targeting human FAP in the human anti-FAP sequence is connected to the C-terminus of the heavy chain, and a human IL-12 sequence containing amino acid mutations (four) involved in heparin binding forms a knob-in-the-hole structure and removes the effector function.

[0354] T1.08 (seq1, seq3, seq9) is a bispecific antibody in which a scFv targeting human FAP in the human anti-FAP sequence is connected to the C-terminus of the light chain, and the human IL-12 sequence forms a knob-in-the-hole structure and removes the effector function.

[0355] T1.09 (seq1, seq5, seq9) is a bispecific antibody in which a scFv targeting human FAP in the human anti-FAP sequence is connected to the C-terminus of the light chain, and a human IL-12 sequence containing amino acid mutations (four) involved in heparin binding forms a knob-in-the-hole structure and removes the effector function.

[0356] T1.10 (seq1, seq2, seq10) is an antibody in which a human anti-FAP sequence targeting human FAP and a human anti-FAP sequence in which a human IL-12 sequence is connected to the C-terminus of the heavy chain form a knob-in-hole structure.

[0357] T1.11 (seq1, seq2, seq11) is an antibody in which a human anti-FAP sequence targeting human FAP and a human IL-12 sequence containing amino acid mutations (four) involved in heparin binding are connected to the C-terminus of the heavy chain to form a knob-in-hole structure.

[0358] T1.12 (seq1, seq2, seq12) is an antibody in which the effector function of the knob-in-the-pore structure with only the human anti-FAP sequence targeting human FAP is removed.

[0359] T1.13 (seq3, seq13) is an antibody in which only the knob-in-the-hole structure with the human IL-12 sequence has its effector function removed.

[0360] T1.14 (seq4, seq13) is an antibody in which only the effector function of the knob-in-the-hole structure of the human IL-12 sequence containing amino acid mutations (two) involved in heparin binding is removed.

[0361] T1.15 (seq5, seq13) is an antibody in which only the effector function of the knob-in-the-hole structure of the human IL-12 sequence containing amino acid mutations (four) involved in heparin binding is removed.

[0362] T1.16 (seq2, seq14) is a human anti-FAP antibody targeting human FAP.

[0363] T1.17 (seq15) is an Fc fusion protein that has only the human IL-12 sequence containing four amino acid mutations involved in heparin binding.

[0364] T1.18 (seq3, seq16, seq17) is a bispecific antibody in which the human anti-CD20 sequence targeting human CD20 and the human IL-12 sequence form a knob-in-the-hole structure and remove the effector function.

[0365] T1.19 (seq4, seq16, seq17) is a bispecific antibody in which a human anti-CD20 sequence targeting human CD20 and a human IL-12 sequence containing two amino acid mutations involved in heparin binding form a knob-in-hole structure and eliminate effector function.

[0366] T1.20 (seq5, seq16, seq17) is a bispecific antibody in which a human anti-CD20 sequence targeting human CD20 and a human IL-12 sequence containing four amino acid mutations involved in heparin binding form a knob-in-hole structure and remove effector function.

[0367] T1.21 (seq12, seq16, seq17) is an antibody in which only the effector function of the knob-in-the-hole structure with a human anti-CD20 sequence targeting human CD20 is removed.

[0368] T1.23 (seq1, seq2, seq292) is a bispecific antibody comprising a human anti-FAP sequence and a human IL-12 sequence, wherein the scFv of the human anti-FAP sequence is connected to the C-terminus to form a knob-in-the-hole structure and the effector function is removed.

[0369] T1.24 (seq1, seq2, seq293) is a bispecific antibody, in which a human anti-FAP heavy chain sequence and a human IL-12 sequence containing amino acid mutations (four) involved in heparin binding, wherein the scFv of the human anti-FAP sequence is connected to the C-terminus to form a knob-in-the-hole structure and the effector function is removed.

[0370] T1.25 (seq2, seq294) is an Fc fusion protein dimer containing a human anti-FAP sequence, in which a human IL-12 sequence is linked to the C-terminus of the heavy chain.

[0371] T1.26 (seq2, seq295) is an Fc fusion protein dimer containing a human anti-FAP sequence, in which a human IL-12 sequence containing four amino acid mutations involved in heparin binding is linked to the C-terminus of the heavy chain.

[0372] T1.27 (seq296) ​​is an Fc fusion protein dimer composed of the human IL-12 sequence, in which the single-chain fragment variable region (scFv) of the human anti-FAP sequence is linked to the C-terminus.

[0373] T1.28 (seq297) is an Fc fusion protein dimer composed of a human IL-12 sequence containing four amino acid mutations involved in heparin binding, in which a scFv of a human anti-FAP sequence is linked to the C-terminus.

[0374] [seq1] Anti-hu FAP HC hu IgG1 Fc knob DANG

[0375] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0376] [seq2] Anti - hu FAP LC

[0377] DIVMTQSPDSLAVSLGERATINCKSSQSLLYSRNQKNYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGFGTDFTLTISSLQAEDVAVYYCQQYFSYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0378] [seq3] hu scIL - 12 - hu IgG1 Fc Kong DANG

[0379] IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0380] [seq4]hu scIL-12 mut1-hu IgG1 Fc pore DANG

[0381] IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGASKREAKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0382] [seq5]hu scIL-12 mut2-hu IgG1 Fc pore DANG

[0383] IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGASAREAADRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0384] [seq6](Anti - hu FAP VH)2 - hu IgG1 Fc Knob DANG

[0385] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0386] [seq7](Anti - hu FAP VL)2

[0387] DIVMTQSPDSLAVSLGERATINCKSSQSLLYSRNQKNYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGFGTDFTLTISSLQAEDVAVYYCQQYFSYPLTFGQGTKVEIKGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSLLYSRNQKNYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGFGTDFTLTISSLQAEDVAVYYCQQYFSYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0388] [seq8] anti - hu FAP HC hu IgG1 Fc knob DANG - anti - hu FAP scFv

[0389] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSLLYSRNQKNYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGFGTDFTLTISSLQAEDVAVYYCQQYFSYPLTFGQGTKVEIK

[0390] [seq9] Anti-hu FAP LC - Anti-hu FAP scFv

[0391] DIVMTQSPDSLAVSLGERATINCKSSQSLLYSRNQKNYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGFGTDFTLTISSLQAEDVAVYYCQQYFSYPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSSGGGGSGGGGSGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSLLYSRNQKNYLAWYQQKPGQPPKLLIFWASTRESGVPDRFSGSGFGTDFTLTISSLQAEDVAVYYCQQYFSYPLTFGQGTKVEIK

[0392] [seq10] anti-hu FAP HC hu IgG1 Fc pore DANG-hu scIL-12

[0393] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTSSASTKGPSVFPLAPSSKSTGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGSGGGSGIWELKKDVYVVELDWYPDAPGEMVV LTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVPDTWSTPHSYFSLTFCVQVQGKSKREKDRVFTDK TSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPPDFYKTKIKLCILLHAFRIVTIDRVMSYLNAS

[0394] [seq11] Anti-hu FAP HC hu IgG1 Fc well DANG-hu scIL-12mut2

[0395] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTSSASTKGPSVFPLAPSSKSTGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGSGGGSGIWELKKDVYVVELDWYPDAPGEMVV LTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVPDTWSTPHSYFSLTFCVQVQGASAREAADRVFTDK TSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPPDFYKTKIKLCILLHAFRIVTIDRVMSYLNAS

[0396] [seq12]hu IgG1 Fc Kong DANG

[0397] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0398] [seq13]hu IgG1 Fc Knob DANG

[0399] DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0400] [seq14]Anti - hu FAP HC hu IgG1 Fc DANG

[0401] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0402] [seq15]hu scIL-12mut2-hu IgG1 Fc DANG

[0403] IWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGASAREAADRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASGGGGSGGGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0404] [seq16] Anti - hu CD20 HC hu IgG1 Fc Knob DANG

[0405] QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[0406] [seq17] Anti - hu CD20 LC

[0407] QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

[0408] [seq292] hu scIL - 12 - hu IgG1 Fc pore DANG - anti - hu FAP scFv

[0409]

[0410] [seq293]hu scIL-12mut2-hu IgG1 Fc well DANG-anti-hu FAP scFv

[0411]

[0412] [seq294]Anti-hu FAP HC hu IgG1 Fc DANG-hu scIL-12

[0413] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTSSASTKGPSVFPLAPSSKSTGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGSGGGSGIWELKKDVYVVELDWYPDAPGEMVV LTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVPDTWSTPHSYFSLTFCVQVQGKSKREKDRVFTDK TSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPPDFYKTKIKLCILLHAFRIVTIDRVMSYLNAS

[0414] [seq295] Anti-hu FAP HC hu IgG1 Fc DANG-hu scIL-12mut2

[0415] QVQLVQSGAEVKKPGASVKVSCKTSRYTFTEYTIHWVRQAPGQRLEWIGGINPNNGIPNYNQKFKGRVTITVDTSASTAYMELSSLRSEDTAVYYCARRRIAYGYDEGHAMDYWGQGTLVTSSASTKGPSVFPLAPSSKSTGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPPKPKDTLMISRTPEVTCVVVAVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYGSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGGGGSGGGSGGGSGIWELKKDVYVVELDWYPDAPGEMVV LTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVPDTWSTPHSYFSLTFCVQVQGASAREAADRVFTDK TSATVICRKNASISVRAQDRYYSSSWSEWASVPCSGGGGSGGGGSGGGGSRNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPPDFYKTKIKLCILLHAFRIVTIDRVMSYLNAS

[0416] [seq296] hu scIL-12-hu IgG1 Fc DANG-anti-hu FAP scFv

[0417]

[0418] [seq297] hu scIL-12mut2-hu IgG1 Fc DANG-anti-hu FAP scFv

[0419]

[0420] Preparation Example 2. Overview of mouse fusion protein anti-FAP / IL-12 IgG2a DANG

[0421] [Table 2]

[0422]

[0423]

[0424] [seq18] consists of a mouse anti-FAP heavy chain variable region sequence and a mouse IgG2a Fc, in which the effector function is removed by the DANG mutation (D265A, N297G) and the knob structure is formed by the T321W mutation.

[0425] [seq19] consists of mouse anti-FAP light chain sequence.

[0426] [seq20] consists of the mouse IL-12p40 (β) region sequence, the linker GGGGSGGGGSGGGGS, the mouse IL-12p35 (α) region sequence, the linker GGGGSGGGGS and the mouse IgG2a Fc, in which the effector function is removed by the DANG mutation, and the pore structure is formed by the T321S, M323A and Y362V mutations.

[0427] [seq21] consists of a sequence in which the lysine (K) at amino acids 277 and 282 involved in heparin binding in the mouse IL-12p40 (β) region are mutated to alanine (A), the linker GGGGSGGGGSGGGGS, the sequence of the mouse IL-12p35 (α) region, the linker GGGGSGGGGS, and the mouse IgG2a Fc pore DANG.

[0428] [seq22] consists of a sequence in which the arginine (R) at amino acid position 276 and the lysine (K) at amino acids 277, 278, and 282 in the mouse IL-12p40 (β) region involved in heparin binding are mutated to alanine (A), the linker GGGGSGGGGSGGGGS, the sequence of the mouse IL-12p35 (α) region, the linker GGGGSGGGGS, and the mouse IgG2a Fc pore DANG.

[0429] [seq23] consists of the mouse anti-FAP heavy chain variable region sequence, the linker GGGGSGGGGSGGGGS, the mouse anti-FAP heavy chain variable region sequence and the mouse IgG2a Fc knob DANG.

[0430] [seq24] consists of the mouse anti-FAP light chain variable region sequence, the linker GGGGSGGGGSGGGGS and the mouse anti-FAP light chain sequence.

[0431] [seq25] consists of the mouse anti-FAP heavy chain variable region sequence, the mouse IgG2a Fc knob DANG, the linker GGGGSGGGGSGGGGS, the mouse anti-FAP heavy chain variable region sequence, the linker GGGGSGGGGSGGGGSGG GGS and the mouse anti-FAP light chain variable region sequence.

[0432] [seq26] consists of a mouse anti-FAP light chain sequence, a linker GGGGSGGGGSGGGGS, a mouse anti-FAP heavy chain variable region sequence, a linker GGGGSGGGGSGGGGSGGGGS and a mouse anti-FAP light chain variable region sequence.

[0433] [seq27] consists of the mouse anti-FAP heavy chain sequence, mouse IgG2a Fc pore DANG, linker GGGGSGGGGSGGGGS, mouse IL-12 p40 (β) region sequence, linker GGGGSGGGGSGGGGS and mouse IL-12 p35 (α) region sequence.

[0434] [seq28] consists of the mouse anti-FAP heavy chain sequence, the mouse IgG2a Fc pore DANG, the linker GGGGSGGGGSGGGGS, the p40 (β) region sequence of mouse IL-12 containing four amino acid mutations involved in heparin binding, the linker GGGGSGGGGSGGGGS and the mouse IL-12 p35 (α) region sequence.

[0435] [seq29] consists only of mouse IgG2a Fc pore DANG.

[0436] [seq30] consists only of the mouse IgG2a Fc knob DANG.

[0437] [seq31] consists of mouse anti-FAP heavy chain variable region and mouse IgG2a Fc DANG.

[0438] [seq32] consists of the p40(β) region sequence of mouse IL-12 containing four amino acid mutations involved in heparin binding, the linker GGGGSGGGGSGGGGS, the mouse IL-12 p35(α) region sequence, the linker GGGGSGGGGS and mouse IgG2aFc DANG.

[0439] [seq33] consists of the heavy chain variable region sequence of mouse anti-CD20 antibody 18B12 and mouse IgG2a knob DANG.

[0440] [seq34] consists of the light chain sequence of mouse anti-CD20 antibody 18B12.

[0441] [seq35] consists only of mouse IgG2a Fc DANG.

[0442] [seq298] consists of mouse IL-12p40 (β) region sequence, linker GGGGSGGGGSGGGGS, mouse IL-12p35 (α) region sequence, linker GGGGSGGGGS and mouse IgG2a Fc pore DANG, linker GGGGSGGGGSGGGGS, mouse anti-FAP heavy chain variable region sequence, linker GGGGSGGGGSGGGGSGGGGS and mouse anti-FAP light chain variable region sequence.

[0443] [seq299] consists of a mouse IL-12p40 (β) region sequence containing four amino acid mutations involved in heparin binding, a linker GGGGSGGGGSGGGGS, a mouse IL-12p35 (α) region sequence, a linker GGGGSGGGGS and a mouse IgG2a Fc pore DANG, a linker GGGGSGGGGSGGGGS, a mouse anti-FAP heavy chain variable region sequence, a linker GGGGSGGGGSGGGGSGGGGS and a mouse anti-FAP light chain variable region sequence.

[0444] [seq300] consists of the mouse anti-FAP heavy chain sequence, mouse IgG2a Fc DANG, the linker GGGGSGGGGSGGGGS, the p40(β) region sequence of mouse IL-12, the linker GGGGSGGGGSGGGGS and the mouse IL-12 p35(α) region sequence.

[0445] [seq301] consists of the mouse anti-FAP heavy chain sequence, mouse IgG1 Fc DANG, the linker GGGGSGGGGSGGGGS, the p40(β) region sequence of mouse IL-12 containing four amino acid mutations involved in heparin binding, the linker GGGGSGGGGSGGGGS and the mouse IL-12 p35(α) region sequence.

[0446] [seq302] consists of mouse IL-12p40 (β) region sequence, linker GGGGSGGGGSGGGGS, mouse IL-12p35 (α) region sequence, linker GGGGSGGGGS and mouse IgG2a Fc DANG, linker GGGGSGGGGSGGGGS, mouse anti-FAP heavy chain variable region sequence, linker GGGGSGGGGSGGGGSGGGGS and mouse anti-FAP light chain variable region sequence.

[0447] [seq303] consists of a mouse IL-12p40 (β) region sequence containing four amino acid mutations involved in heparin binding, a linker GGGGSGGGGSGGGGS, a mouse IL-12p35 (α) region sequence, a linker GGGGSGGGGS and mouse IgG2aFc DANG, a linker GGGGSGGGGSGGGGS, a mouse anti-FAP heavy chain variable region sequence, a linker GGGGSGGGGSGGGGSGGGGS and a mouse anti-FAP light chain variable region sequence.

[0448] T1.01m (seq18, seq19, seq20) is a bispecific antibody in which the mouse anti-FAP sequence targeting mouse FAP and the mouse IL-12 sequence form a knob-in-the-hole structure and remove the effector function.

[0449] T1.02m (seq18, seq19, seq21) is a bispecific antibody in which a mouse anti-FAP sequence targeting mouse FAP and a mouse IL-12 sequence containing two amino acid mutations involved in heparin binding form a knob-in-the-hole structure and eliminate effector function.

[0450] T1.03m (seq18, seq19, seq22) is a bispecific antibody in which a mouse anti-FAP sequence targeting mouse FAP and a mouse IL-12 sequence containing four amino acid mutations involved in heparin binding form a knob-in-hole structure and eliminate effector function.

[0451] T1.04m (seq20, seq23, seq24) is a bispecific antibody in which the mouse anti-FAP sequence and the mouse IL-12 sequence targeting mouse FAP in the form of a dual variable domain immunoglobulin (DVD-Ig) form a knob-in-the-hole structure and remove the effector function.

[0452] T1.05m (seq22, seq23, seq24) is a bispecific antibody in which a mouse anti-FAP sequence targeting mouse FAP in the form of DVD-Ig and a mouse IL-12 sequence containing amino acid mutations (four) involved in heparin binding form a knob-in-hole structure and remove the effector function.

[0453] T1.06m (seq19, seq20, seq25) is a bispecific antibody in which a single-chain variable fragment (scFv) of a mouse anti-FAP sequence targeting mouse FAP is included at the C-terminus of the heavy chain and a mouse IL-12 sequence forms a knob-in-the-hole structure and removes the effector function.

[0454] T1.07m (seq19, seq22, seq25) is a bispecific antibody in which a scFv of a mouse anti-FAP sequence targeting mouse FAP is included at the C-terminus of the heavy chain and a mouse IL-12 sequence containing amino acid mutations (four) involved in heparin binding forms a knob-in-the-hole structure and removes the effector function.

[0455] T1.08m (seq18, seq20, seq26) is a bispecific antibody in which a scFv targeting mouse FAP in the mouse anti-FAP sequence is included at the C-terminus of the light chain and the mouse IL-12 sequence forms a knob-in-the-hole structure and removes the effector function.

[0456] T1.09m (seq18, seq22, seq26) is a bispecific antibody in which a scFv targeting mouse FAP in a mouse anti-FAP sequence is included at the C-terminus of the light chain and a mouse IL-12 sequence containing amino acid mutations (four) involved in heparin binding forms a knob-in-the-hole structure and removes the effector function.

[0457] T1.10m (seq18, seq19, seq27) is an antibody in which a mouse anti-FAP sequence targeting mouse FAP and a mouse anti-FAP sequence in which a mouse IL-12 sequence is connected to the C-terminus of the heavy chain form a knob-in-hole structure.

[0458] T1.11m (seq18, seq19, seq28) is an antibody in which a mouse anti-FAP sequence targeting mouse FAP and a mouse IL-12 sequence containing amino acid mutations (four) involved in heparin binding are connected to the C-terminus of the heavy chain to form a knob-in-hole structure.

[0459] T1.12m (seq18, seq19, seq29) is an antibody in which the effector function of the knob-in-the-hole structure with only the mouse anti-FAP sequence targeting mouse FAP is removed.

[0460] T1.13m (seq20, seq30) is an antibody in which only the effector function of the knob-in-the-hole structure with the mouse IL-12 sequence is removed.

[0461] T1.14m (seq21, seq30) is an antibody in which only the effector function of the knob-in-the-hole structure of the mouse IL-12 sequence containing amino acid mutations (two) involved in heparin binding is eliminated.

[0462] T1.15m (seq22, seq30) is an antibody in which only the effector function of the knob-in-the-hole structure of the mouse IL-12 sequence containing amino acid mutations (four) involved in heparin binding is eliminated.

[0463] T1.16m (seq19, seq31) is a mouse anti-FAP antibody targeting mouse FAP.

[0464] T1.17m (seq32) is an Fc fusion protein dimer that has only the mouse IL-12 sequence containing four amino acid mutations involved in heparin binding.

[0465] T1.18m (seq20, seq33, seq34) is a bispecific antibody in which the mouse anti-CD20 (18B12) sequence targeting mouse CD20 and the mouse IL-12 sequence form a knob-in-the-hole structure and eliminate the effector function.

[0466] T1.19m (seq21, seq33, seq34) is a bispecific antibody in which a mouse anti-CD20 (18B12) sequence targeting mouse CD20 and a mouse IL-12 sequence containing two amino acid mutations involved in heparin binding form a knob-in-hole structure and eliminate effector function.

[0467] T1.20m (seq22, seq33, seq34) is a bispecific antibody in which a mouse anti-CD20 sequence targeting mouse CD20 and a mouse IL-12 sequence containing four amino acid mutations involved in heparin binding form a knob-in-hole structure and eliminate effector function.

[0468] T1.21m (seq29, seq33, seq34) is an antibody in which the effector function of the knob-in-the-hole structure with only the mouse anti-CD20 sequence targeting mouse CD20 is removed.

[0469] T1.22m (seq35) is a protein with only the mouse Fc sequence, in which the effector function is removed.

[0470] T1.23m (seq18, seq19, seq298) is a bispecific antibody in which a mouse anti-FAP sequence and a mouse IL-12 sequence (in which the scFv of the mouse anti-FAP sequence is connected to the C-terminus) form a knob-in-the-hole structure and remove the effector function.

[0471] T1.24m (seq18, seq19, seq299) is a bispecific antibody comprising a mouse anti-FAP heavy chain sequence and a mouse IL-12 sequence containing amino acid mutations (four) involved in heparin binding, wherein the scFv of the mouse anti-FAP sequence is connected to the C-terminus to form a knob-in-the-hole structure and the effector function is removed.

[0472] T1.25m (seq19, seq300) is an Fc fusion protein dimer containing a mouse anti-FAP sequence, in which a mouse IL-12 sequence is linked to the C-terminus of the heavy chain.

[0473] T1.26m (seq19, seq301) is an Fc fusion protein dimer containing a mouse anti-FAP sequence, in which a mouse IL-12 sequence containing four amino acid mutations involved in heparin binding is linked to the C-terminus of the heavy chain.

[0474] T1.27m (seq302) is an Fc fusion protein dimer composed of a mouse IL-12 sequence, in which a scFv of a mouse anti-FAP sequence is linked to the C-terminus.

[0475] T1.28m (seq303) is an Fc fusion protein dimer composed of a mouse IL-12 sequence containing four amino acid mutations involved in heparin binding, with a scFv of a mouse anti-FAP sequence linked to the C-terminus.

[0476] [seq18] Anti-mu FAP HC mu IgG2a Fc knob DANG

[0477] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLWCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0478] [seq19] Anti-mu FAP LC

[0479] QIVLTQSPAIMSASPGEKVTMTCSASSGVNFMHWYQQKSGTSPKRWIFDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSFNPPTFGGGTKLEIKRADAAPTV

[0480] SIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWK

[0481] IDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

[0482] [seq20] mu scIL-12-mu IgG2a Fc pore DANG

[0483] MWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSAGGGGSGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLSCAVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0484] [seq21] mu scIL-12mut1-mu IgG2a Fc pore DANG

[0485] MWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRAKEKMAETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSAGGGGSGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLSCAVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0486] [seq22]mu scIL-12mut2-mu IgG2a Fc pore DANG

[0487] MWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQAAAEKMAETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSAGGGGSGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLSCAVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0488] [seq23](Anti-mu FAP VH)2, mu IgG2a Fc knob DANG

[0489] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAGGGGSGGGGSGGGGSQVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLWCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0490] [seq24](Anti-mu FAP VL)2

[0491] QIVLTQSPAIMSASPGEKVTMTCSASSGVNFMHWYQQKSGTSPKRWIFDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSFNPPTFGGGTKLEIKGGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMTCSASSGVNFMHWYQQKSGTSPKRWIFDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSFNPPTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

[0492] [seq25]Anti-mu FAP HC mu IgG2a Fc knob DANG - Anti-mu FAP scFv

[0493] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLWCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGKGGGGSGGGGSGGGGSGGGGSQVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAGGGGSGGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMTCSASSGVNFMHWYQQKSGTSPKRWIFDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSFNPPTFGGGTKLEIK

[0494] [seq26]Anti-mu FAP LC - Anti-mu FAP scFv

[0495] QIVLTQSPAIMSASPGEKVTMTCSASSGVNFMHWYQQKSGTSPKRWIFDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSFNPPTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNECGGGGSGGGGSGGGGSQVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAGGGGSGGGGSGGGGSGGGGSQIVLTQSPAIMSASPGEKVTMTCSASSGVNFMHWYQQKSGTSPKRWIFDTSKLASGVPARFSGSGSGTSYSLTISSMEAEDAATYYCQQWSFNPPTFGGGTKLEIK

[0496] [seq27] Anti-mu FAP HC mu IgG2a Fc pore DANG-mu scIL-12

[0497] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLSCAVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSGGGGSMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA

[0498] [seq28] Anti-mu FAP HC mu IgG2a Fc pore DANG-mu scIL-12mut2

[0499] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLSCAVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSGGGGSMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQAAAEKMAETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA

[0500] [seq29] mu IgG2a Fc pore DANG

[0501] EPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLSCAVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMVSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0502] [seq30] mu IgG2a Fc knob DANG

[0503] EPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLWCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0504] [seq31] Anti-mu FAP HC mu IgG2a Fc DANG

[0505] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0506] [seq32]mu scIL-12mut2-mu IgG2a Fc DANG

[0507] MWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQAAAEKMAETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSAGGGGSGGGGSEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0508] [seq33] Anti-mu CD20 HC mu IgG2a Fc knob DANG

[0509] QVQLQQPGAELVRPGTSVKLSCKASGYTFTSYWMHWIKQRPGQGLEWIGVIDPSDNYTKYNQKFKGKATLTVDTSSSTAYMQLSSLTSEDSAVYFCAREGYYGSSPWFAYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLWCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0510] [seq34] Anti-mu CD20 LC

[0511] QIVMSQSPAILSASPGEKVTMTCRARSSVSYIHWYQQKPGSSPKPWIYATSNLASGVPGRFSGSGSGTSYSLTITRVEAEDAATYYCQQWSSKPPTFGGGTKLEIKRTDAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC

[0512] [seq35] mu IgG2a Fc DANG

[0513] EPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK

[0514] [seq298] mu scIL-12-mu IgG2a Fc pore DANG-anti-mu FAP scFv

[0515]

[0516] [seq299] mu scIL-12mut2-mu IgG2a Fc pore DANG-anti-mu FAP scFv

[0517]

[0518] [seq300]Anti-mu FAP HC mu IgG2a Fc DANG-mu scIL-12

[0519] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSGGGGSMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQRKKEKMKETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA

[0520] [seq301]Anti-mu FAP HC mu IgG2a Fc DANG-mu scIL-12mut2

[0521] QVQLQQSGAELARPGASVNLSCKASGYTFTNNGINWLKQRTGQGLEWIGEIYPRSTNTLYNEKFKGKATLTADRSSNTAYMELRSLTSEDSAVYFCARTLTAPFAFWGQGTLVTVSAAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVAVSEDDPDVQISWFVNNVEVHTAQTQTHREDYGSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGGGGGSGGGGSGGGGSMWELEKDVYVVEVDWTPDAPGETVNLTCDTPEEDDITWTSDQRHGVIGSGKTLTITVKEFLDAGQYTCHKGGETLSHSHLLLHKKENGIWSTEILKNFKNKTFLKCEAPNYSGRFTCSWLVQRNMDLKFNIKSSSSSPDSRAVTCGMASLSAEKVTLDQRDYEKYSVSCQEDVTCPTAEETLPIELALEARQQNKYENYSTSFFIRDIIKPDPPKNLQMKPLKNSQVEVSWEYPDSWSTPHSYFSLKFFVRIQAAAEKMAETEEGCNQKGAFLVEKTSTEVQCKGGNVCVQAQDRYYNSSCSKWACVPCRVRSGGGGSGGGGSGGGGSRVIPVSGPARCLSQSRNLLKTTDDMVKTAREKLKHYSCTAEDIDHEDITRDQTSTLKTCLPLELHKNESCLATRETSSTTRGSCLPPQKTSLMMTLCLGSIYEDLKMYQTEFQAINAALQNHNHQQIILDKGMLVAIDELMQSLNHNGETLRQKPPVGEADPYRVKMKLCILLHAFSTRVVTINRVMGYLSSA

[0522] [seq302]mu scIL-12-mu IgG2a Fc DANG-anti-mu FAP scFv

[0523]

[0524] [seq303] mu scIL-12mut2-mu IgG2a Fc DANG-anti-mu FAP scFv

[0525]

[0526] Manufacturing Example 1. Production of fusion protein

[0527] Reagents and equipment are shown in Tables 3 and 4 below.

[0528] [Table 3]

[0529]

[0530] [Table 4]

[0531] Equipment and Tools Manufacturer model Biosafety cabinet NUAIRE LabGard class± Centrifuge Eppendorf 5424 Gel Imaging System Tanon 2500R

[0532] The synthesized DNA fragment was amplified by PCR, and the PCR product was gel purified. The pTT5 vector was cut with restriction endonucleases EcoRI and BamHI, and then gel purified. Each PCR product and the linear vector were connected using the In-Fusion kit. The resulting vector was transformed into ECOS101 DH5α competent cells, and the cells were cultured on 2×YT agar plates containing 100μg / ml ampicillin. All operations were performed according to standard transformation methods. Positive recombinants were identified by colony PCR, and the recombinant plasmids were sequenced for sequence verification. Single colonies were selected, and the seed culture was inoculated into 5ml of 2×YT medium containing 100μg / ml ampicillin. Shake and culture at 37°C for 8 hours.

[0533] Afterwards, the seed culture was diluted 1:1,000 in 200 ml of selective 2×YT medium. Incubate at 37°C with shaking for 16 hours. Bacterial cells were harvested by centrifugation at 4°C, 4,700 rpm for 10 minutes. The bacterial pellet was resuspended in 12 ml of RES-EF buffer. Afterwards, 12 ml of LYS-EF buffer was added, the sealed tube was vigorously inverted to mix well, and then incubated at room temperature for 5 minutes. 12 ml of NEU-EF buffer was added to the lysate and vigorously inverted to mix well and quickly.

[0534] Inject the lysate into Before filtering the Xtra column, prepare a homogenous suspension of the precipitate by inverting the lysate tube 3 times to prevent clogging of the filter. Thereafter, wash with 10 ml of filter wash buffer FIL-EF. Xtra Column Filters and Xtra Column. Remove by pulling or flipping the column Xtra column filter. Wash with 90 ml of wash buffer ENDO Xtra column.

[0535] Wash with 45 ml of Wash Buffer WASH-EF Xtra column. Elute the plasmid DNA with 15 ml of elution buffer ELU. Collect the eluate in a 50 ml centrifuge tube. Add 10.5 ml of isopropanol at room temperature to precipitate the eluted plasmid DNA. After vortexing, let the mixture stand for 2 minutes.

[0536] Afterwards, add 5 ml of 70% ethanol to the pellet. Carefully remove the ethanol completely from the tube using a pipette tip. Dry the pellet at room temperature (20°C). Afterwards, wash with 1,000 μl of H 2 HO to dissolve the DNA pellet.

[0537] Manufacturing Example 2. Cell transfection and protein expression

[0538] Manufacturing Example 2.1. Cell transfection

[0539] The materials and reagents used are shown in Table 5 below.

[0540] [Table 5]

[0541]

[0542]

[0543] Maintain the 293F seed strain containing complete medium at 130 rpm, 37 °C and 8% CO. 2 In a shaking incubator. 6 Cells were cultured at a density of 2.6 × 10 cells / ml and the medium was changed every 2 to 3 days. 24 hours before transfection, the new passage number was 2.6 × 10 6 The prepared cells were placed in a shaking incubator at 130 rpm, 37°C and 8% CO 2 On the day of transfection, the cell density was adjusted to 5.0×10 6 The density of cells / ml was 1 L in a 3 L shake flask. 0.4 mg of HC and 0.6 mg of LC plasmids were diluted with 50 ml of OPTI MEM I and filtered through a 0.22 μm filter. Thereafter, 2 mg of PEI was diluted with 50 ml of OPTI MEM I to prepare the transfection reagent.

[0544] The diluted PEI was added to the DNA mixture and then mixed immediately. Thereafter, the mixture was incubated at room temperature for 15 minutes. The DNA-PEI mixture was added to a 2.6 × 10 6 Afterwards, the cells were placed in a shaking incubator at 130 rpm, 37°C and 8% CO 2Continuously culture for 24 hours under the conditions of 10% peptone. 24 hours after transfection, 10% peptone was added to 1 / 20 of the culture medium to a final concentration of 0.5%. Thereafter, the cells were placed in a shaking incubator at 130 rpm, 37°C and 8% CO 2 Continuously culture under the conditions of .Measure and record cell density / viability every day for 2 to 5 days after transfection.Harvest cells for purification 7 days after transfection or when cell viability is less than 70%.

[0545] Production Example 2.2. Protein purification

[0546] The reagents, buffer compositions and equipment used for protein purification are shown in Tables 6 to 8 below.

[0547] [Table 6]

[0548]

[0549]

[0550] [Table 7]

[0551]

[0552] [Table 8]

[0553] equipment Manufacturer model AKTA Pure GE Healthcare 29-0182-24 Centrifuge Beckman J-26xp Gel Imaging System Tanon 2500R Sartopore 2 filter Sartorius 5445307H9-OO-A

[0554] The protein was purified using a Mabselect confirmed column. Specifically, the supernatant was harvested by centrifugation at 2,000×g, 4°C for 20 minutes. Thereafter, the supernatant was filtered with a Sartopore 2 filter. The clarified supernatant was loaded onto a 5ml MabSelect Sure column equilibrated with buffer A. Thereafter, the column was washed with buffer A until the A280 absorbance reached baseline. The column was washed with 10CV buffer B. The column was washed with 10CV buffer A. The bound protein was eluted with 6CV buffer C, and 1 / 6 volume of buffer D was added to neutralize the eluted material. SDS-PAGE and SEC-HPLC analysis were performed. Thereafter, the protein was purified using a HIC column. The protein was then dialyzed overnight with buffer E at 4°C. The supernatant was loaded onto a HIC column equilibrated with buffer E. Thereafter, the column was washed with buffer E until the A280 absorbance reached baseline. The bound protein was eluted by gradient elution (10CV buffer F 0%-40%). Bound proteins were eluted with 2CV 100% buffer F. SDS-PAGE analysis was performed.

[0555] After protein purification, the protein was collected at one location and then dialyzed against the final buffer at 4°C overnight. Thereafter, SDS-PAGE and SEC-HPLC analysis were performed.

[0556] The results are as follows Figures 1 to 6 As shown, the human protein and the mouse protein of one embodiment were found to be purified.

[0557] Manufacturing Example 3. Optimizing the production of bispecific antibodies

[0558] Manufacturing Example 3.1. Identification of Optimization of Production of Fusion Proteins Comprising Human IL-12

[0559] Table 9 below shows changes in human anti-FAP / IL-12 bispecific antibodies produced according to human IL-12 mutations. The brackets indicate the production scale of the protein, in L. The number before the bracket is the yield per liter obtained by dividing the amount of protein by the production scale.

[0560] [Table 9]

[0561]

[0562] As shown in Table 9 above, as the number of amino acid mutations involved in heparin binding in the human IL-12p40 (β) region increases, the amount of protein increases after protein purification by a protein A column (MabSelect Sure column). It was found that the yield of bispecific antibody T1.02 in which lysine (K) at amino acids 280 and 285 was mutated to alanine (A) was increased compared to T1.01. It was found that the yield of bispecific antibody T1.03 in which lysine (K) at amino acids 280, 282, 285 and 286 was mutated to alanine (A) was increased by about 2.5 times compared to T1.01.

[0563] Manufacturing Example 3.2. Identification of optimization of production of fusion protein containing mouse IL-12

[0564] Table 10 below shows changes in mouse anti-FAP / IL-12 bispecific antibodies generated according to mouse IL-12 mutations.

[0565] [Table 10]

[0566]

[0567] As shown in the above Table 10, as the number of amino acid mutations in the region of mouse IL-12p40(β) involved in heparin binding increased, the amount of protein increased after the protein was purified by a protein A column (MabSelect Sure column).

[0568] In each table, the amount of protein after passing through the protein A column was compared by dividing the total protein yield by the production scale. The results showed that the bispecific antibody T1.02m in which the lysine (K) at the 277th and 282nd amino acids was mutated to alanine (A) and the arginine (R) at the 276th amino acid was mutated to alanine (A), and the bispecific antibody T1.03m in which the lysine (K) at the 277th, 278th and 282nd amino acids was mutated to alanine (A) gradually increased in protein yield compared with T1.01m and T1.02m. In addition, it was found that the yield of T1.03m using the CHO cell line was increased by about 13 times compared with that using the HEK 293 cell line.

[0569] Manufacturing Example 4. Cell lines and cell line culture

[0570] HEK-Blue IL-12 cell line was transformed into HEK293 cells, human embryonic kidney fibroblasts, with IL-12 receptor gene and STAT4-induced SEAP reporter gene, obtained from Invivogen (San Diego, USA). HEK-Blue IL-12 cells were maintained in DMEM (GIBCO) selection medium containing 10% FBS (GIBCO), 100 μg / ml neomycin and 1× HEK-Blue.

[0571] Human embryonic kidney fibroblast cell line HEK293, mouse colorectal cancer cell line CT26-WT, mouse melanoma cell line B16F10 and mouse fibroblast cell line NIH-3T3 were obtained from ATCC (American Type Culture Collection, Manassas, Virginia, USA). HEK293 cells, B16F10 cells and NIH-3T3 cells were maintained in DMEM (GIBCO) containing 10% FBS (GIBCO). A cell line (HEK293-hFAP) in which human FAP (fibroblast activation protein alpha) was overexpressed in HEK293 cells was prepared using a lentivirus capable of delivering the human FAP gene. HEK293-hFAP cells were maintained in DMEM (GIBCO) containing 10% FBS (GIBCO) and 5 μg / ml puromycin.

[0572] Mouse FAP (fibroblast activation protein α) was overexpressed in CT26-WT cells, B16F10 cells, and NIH-3T3 cells using a lentivirus capable of delivering the mouse FAP gene (CT26-mFAP, B16F10-mFAP, and NIH-3T3-mFAP). CT26-mFAP cells were stored in RPMI-1640 (GIBCO) containing 10% FBS (GIBCO) and 10 μg / ml puromycin. B16F10-mFAP cells were stored in DMEM (GIBCO) containing 10% FBS (GIBCO) and 10 μg / ml puromycin. NIH-3T3-mFAP cells were stored in DMEM (GIBCO) containing 10% FBS (GIBCO) and 5 μg / ml puromycin.

[0573] Manufacturing Example 5. Isolation and Activation of Human Immune Cells

[0574] Blood packs were obtained from the Korean Red Cross with approval from the Institutional Review Board (IRB), and peripheral blood mononuclear cells (PBMCs) were isolated and frozen. Thawed PBMCs were subjected to positive selection and human NK cells were isolated using the Easy sep (stem cell, Vancouver British Columbia, Canada) kit. The isolated NK cells were activated and stored in RPMI-1640 (GIBCO) and 10% FBS containing 50 IU / ml human recombinant IL-2 (rhIL-2, R&D Systems, Minnesota, USA).

[0575] Thawed PBMCs were subjected to negative selection and human T cells were isolated using the Easy sep (stem cell) kit. Human T cells were cultured on plates coated with 1 μg / ml anti-CD3 (OKT3, Invitrogen) and activated for 72 hours. Human T cells were stored in RPMI-1640 (GIBCO) containing 10% FBS (GIBCO).

[0576] Example 1. Identification of fusion protein binding affinity

[0577] Example 1.1. Identification of fusion protein binding to recombinant human FAP

[0578] The binding of T1.01, T1.02 and T1.03 to recombinant human FAP was identified by surface plasmon resonance (SPR).

[0579] Specifically, the surface of the CM5 chip was activated with a 1:1 mixture of 50nM NHS (N-hydroxysuccinimide) and 200nM EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), and 25μg / ml anti-human IgG (Fc) antibody was fixed at a rate of 10μl / min for 400 seconds. The remaining active ester groups were blocked with 1M ethanolamine. T1.01, T1.02, and T1.03 were diluted to 2μg / ml and reacted on a CM5 chip fixed with anti-human IgG (Fc) antibody. Recombinant human FAP was diluted to 200nM in 1×HBS-EP+ buffer and diluted by serial dilution. The diluted recombinant human FAP reacted at a rate of 30μl / min. The binding and dissociation times were 180 seconds and 400 seconds, respectively. After dissociation, the cells were stabilized for 60 seconds and then regenerated with 10 mM glycine pH 1.5 solution at a rate of 30 μl / min for 30 seconds.

[0580] The results are as follows Figure 7 and Figure 8 As shown, it was found that T1.01, T1.02 and T1.03 could specifically bind to recombinant human FAP.

[0581] The binding of T1.04, T1.05, T1.06, T1.07, T1.08, T1.09, T1.10 and T1.11 to recombinant human CD20 was identified by surface plasmon resonance (SPR). The surface of the CM5 chip was activated with a 1:1 mixture of 50 nM NHS (N-hydroxysuccinimide) and 200 nM EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), and 25 μg / ml anti-human IgG (Fc) antibody was immobilized at a rate of 10 μl / min for 400 seconds. The remaining active ester groups were blocked with 1 M ethanolamine.

[0582] Specifically, human proteins T1.04, T1.05, T1.06, T1.07, T1.08, T1.09, T1.10 and T1.11 were diluted to 1 μg / ml, 1 μg / ml, 1 μg / ml, 0.5 μg / ml, 0.5 μg / ml, 0.5 μg / ml and 1 μg / ml, respectively, and reacted on a CM5 chip immobilized with an anti-human IgG (Fc) antibody. Recombinant human FAP was diluted to 25 nM or 50 nM in 1×HBS-EP+ buffer and diluted by serial dilution. The diluted recombinant human FAP reacted at a rate of 30 μl / min. The binding and dissociation times were 180 seconds and 400 seconds, respectively. After dissociation, it was stabilized for 60 seconds and then regenerated at a rate of 30 μl / min for 30 seconds with a 10 mM glycine pH 1.5 solution.

[0583] The results are shown in Table 11 and Fig. 9 and10 As shown in Table 12 and Table 13, it was found that T1.04, T1.05, T1.06 and T1.07 can bind to recombinant human FAP to specifically target FAP. Fig.11 and 12 As shown, T1.08, T1.09, T1.10, and T1.11 were found to bind to recombinant human FAP to specifically target FAP.

[0584] [Table 11]

[0585]

[0586]

[0587] [Table 12]

[0588]

[0589] Example 1.2. Identification of mouse protein binding to recombinant mouse FAP

[0590] The binding of T1.01m, T1.02m and T1.03m to recombinant mouse FAP was identified by surface plasmon resonance (SPR).

[0591] The surface of the CM5 chip was activated with a 1:1 mixture of 50nM NHS (N-hydroxysuccinimide) and 200nM EDC (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide), and 25μg / ml anti-mouse IgG (Fc) antibody was immobilized at a rate of 10μl / min for 400 seconds. The remaining active ester groups were blocked with 1M ethanolamine. T1.01m, T1.02m, and T1.03m were diluted to 2μg / ml and reacted on the CM5 chip immobilized with anti-mouse IgG (Fc) antibody. Mouse recombinant FAP was diluted to 200nM in 1×HBS-EP+ buffer and diluted by serial dilution. The diluted recombinant mouse FAP was reacted at a rate of 30μl / min. The association and dissociation times were 180 seconds and 400 seconds, respectively. After dissociation, the cells were stabilized for 60 seconds and then regenerated with 10 mM glycine pH 1.5 solution at a rate of 30 μl / min for 30 seconds.

[0592] The results are as follows Fig.13 and 14 As shown, it was found that T1.01m, T1.02m, and T1.03m could bind to recombinant mouse FAP to specifically target FAP.

[0593] Example 1.3. Identification of binding to FAP-expressing cells

[0594] The extent of binding of T1.12, T1.01, T1.02, and T1.03 to HEK293 and HEK293-hFAP cells was characterized.

[0595] Specifically, by dividing 1×10 5 Cell lines were prepared by suspending 1 μg of each of T1.12, T1.01, T1.02 and T1.03 in FACS buffer. Cells were washed twice with FACS buffer. Cells were stained with anti-human IgG antibody (Biolegend). Negative controls were stained with anti-human IgG antibody (Biolegend) only. Expression rates of stained cells were measured using BD LSR and analyzed using FlowJo software.

[0596] The results are as follows Fig.15 As shown, T1.12, T1.01, T1.02, and T1.03 were found to bind to human FAP-expressing cell lines by 99% or more. These results indicate that the fusion protein of one embodiment can bind to human FAP-expressing cell lines to specifically target FAP.

[0597] Furthermore, the extent of binding of T1.12m, T1.01m, T1.02m, and T1.03m to B16F10 and B16F10-mFAP cells was identified.

[0598] Specifically, by dividing 1×10 5 Cell lines were prepared by suspending 1 μg of each of T1.12m, T1.01m, T1.02m and T1.03m in FACS buffer. Cells were washed twice with FACS buffer. Cells were stained with anti-mouse IgG2a antibody (Biolegend). Negative controls were stained with anti-mouse IgG2a antibody (Biolegend) only. Expression rates of stained cells were measured using BD LSR and analyzed using FlowJo software.

[0599] The results are as follows Fig.16 As shown, T1.12m, T1.01m, T1.02m, and T1.03m were found to bind to the FAP-expressing cell line by 99% or more. These results indicate that the fusion protein of one embodiment can bind to the mouse FAP-expressing cell line to specifically target FAP.

[0600] Example 1.4. Identification of the binding of fusion protein to recombinant human IL-12 receptor

[0601] Considering that the fusion protein IL-12 must bind to the IL-12 receptor to exert its effect, it was found that T1.01, T1.02, T1.03 and T1.12 bound to the recombinant human IL-12 receptor.

[0602] T1.01, T1.02 and T1.03 were fixed on the plate and combined with recombinant human IL-12 receptor protein coupled with horseradish peroxidase (HRP). Specifically, the following steps were performed:

[0603] (i) T1.01, T1.02, T1.03 and T1.12 were suspended at 5 μg / ml and diluted by serial dilution. The diluted T1.01, T1.02, T1.03 and T1.12 were aliquoted into a 96-well immunoplate and treated for 24 hours.

[0604] (ii) The wells were washed with a washing solution and then blocked with a 1% BSA (bovine serum albumin, Sigma) solution for 1 hour.

[0605] (iii) The wells were washed with a washing solution and then treated with 1 nM IL-12 receptor β1-biotin (IL-12Rβ1-biotin, Acrobiosystems, Newark, USA) for 2 hours.

[0606] (iv) The wells were washed with washing solution and then treated with streptavidin-HRP for 20 minutes.

[0607] (v) The wells were washed with a washing solution and then treated with a substrate solution for 20 minutes.

[0608] (vi) Treat the wells with stop solution and measure the absorbance at 450 nm.

[0609] The results are as follows Fig.17 As shown, T1.01, T1.02 and T1.03 were found to bind to the recombinant human IL-12 receptor protein in a concentration-dependent manner. T1.12 was used as a control.

[0610] Example 2. Identification of the ability of fusion proteins to induce signal transduction

[0611] Example 2.1. Identification of signal transduction capabilities in IL-12 recognizing cells

[0612] Considering that it is known that IL-12 initiates signal transduction by inducing phosphorylation of the signal mediator STAT4 (signal transducer and activator of transcription 4) when IL-12 binds to the IL-12 receptor, the signal transduction ability of the fusion protein of one embodiment in IL-12 recognizing cells expressing the IL-12 receptor was evaluated.

[0613] Specifically, HEK-Blue IL-12 cell line (IL-12-recognizing cells) was diluted to 2.8×10 5Cells / ml, and distributed at 180 μl / well. Recombinant human IL-12, T1.01m, T1.02m, T1.03m and T1.12m are suspended at 4nM and diluted by serial dilution. HEK-Blue IL-12 cells are treated with diluted recombinant human IL-12, T1.01m, T1.02m, T1.03m and T1.12m. After 24 hours of treatment, cell supernatants are collected and mixed with QU anti-Blue solution (Invivogen) in 96-well plates. Reporter gene expression levels are measured at 620nm using a spectrophotometer (Thermo Fisher).

[0614] The results are as follows Fig.18 As shown, it was identified by 620nm absorbance that in the case of IL-12, T1.01m, T1.02m and T1.03m treatment groups, IL-12 was recognized, and STAT4 expressed the reporter gene by inducing phosphorylation. In contrast, when IL-12 recognition cells were treated with T1.12m, it was found that the control T1.12m did not recognize IL-12. These results indicate that the fusion protein of one embodiment specifically binds to the IL-12 receptor to induce signal transduction.

[0615] Example 2.2. Identification of signaling capabilities in human T cells

[0616] To determine whether IL-12 initiates signaling by inducing phosphorylation of the signaling mediator STAT4 when it binds to the IL-12 receptor of human T cells, human T cells activated with anti-CD3 (OKT3, Invitrogen) were analyzed using the AlphaLISASureFire Ultra p-STAT4 (Tyr693) detection kit (PerkinElmer, MA, USA).

[0617] Specifically, human proteins IL-12, T1.01, T1.02, T1.03 and T1.12 were suspended at 100 ng / ml and diluted by serial dilution. Human T cells activated with anti-CD3 (OKT3, Invitrogen) were treated with diluted recombinant human IL-12, T1.01, T1.02, T1.03 and T1.12. After 2 hours of treatment, the cells were lysed and treated with a reagent (PerkinElmer) for detecting p-STAT4 (phosphorylated STAT4). pSTAT4 was detected with a spectrophotometer at an excitation wavelength of 680 nm and an emission wavelength of 615 nm.

[0618] The results are as follows Fig.19As shown, the half-maximal effective concentration (EC50) of the group treated with recombinant human IL-12 was identified to be 8.945 pM; the EC50 of the T1.01 treatment group was 14.48 pM; the EC50 of the T1.02 treatment group was 56.51 pM; and the EC50 of the T1.03 treatment group was 147.2 pM. In contrast, phosphorylated STAT4 was not detected in the group treated with T1.12 (control group).

[0619] These results suggest that IL-12 mutations weaken T cell signaling capacity.

[0620] Example 2.3. Identification of changes in fusion protein signal transduction ability by low molecular weight heparin in human T cells

[0621] Next, we identified the ability of low molecular weight heparin to enhance the signaling ability of IL-12 mutant (IL-12mut1) fusion protein using human T cells activated with anti-CD3 (OKT3, Invitrogen) and the AlphaLISASureFireUltra p-STAT4 (Tyr693) detection kit.

[0622] In particular, the signaling ability was identified according to the presence or absence of low molecular weight heparin (LMWH) in human T cells by observing whether the phosphorylation induction of the signal mediator STAT4 was attenuated when attenuated IL-12mut2 bound to the IL-12 receptor of human T cells.

[0623] Specifically, recombinant human IL-12, T1.01, T1.02 and T1.03 were suspended at 100 ng / ml and diluted by serial dilution. Activated human T cells were treated with diluted recombinant human IL-12, T1.01, T1.02 and T1.03 together with low molecular weight heparin. After 2 hours of treatment, the cells were lysed and treated with a reagent for detecting p-STAT4 (PerkinElmer). pSTAT4 was detected with a spectrophotometer at an excitation wavelength of 680 nm and an emission wavelength of 615 nm.

[0624] The results are as follows Fig. 20 As shown, the half-maximal effective concentration (EC50) of the group treated with T1.01 and low molecular weight heparin increased by 9.4 times compared with the group treated with T1.01, the half-maximal effective concentration (EC50) of the group treated with T1.02 and low molecular weight heparin increased by 5.5 times compared with the group treated with T1.02, and the half-maximal effective concentration (EC50) of the group treated with T1.03 and low molecular weight heparin increased by 4 times compared with the group treated with T1.03.

[0625] These results suggest that when an IL-12 mutation (IL-12mut2) was added to an existing IL-12 mutation (IL-12mut1), the degree of enhancement of signaling capacity was reduced by the addition of low molecular weight heparin, and thus IL-12 was effectively attenuated.

[0626] Example 3. Identification of cytokine secretion ability of fusion protein

[0627] Example 3.1. Enzyme-linked immunosorbent assay for cytokine measurement

[0628] For cytokine measurement, enzyme-linked immunosorbent assay (ELISA, R&D systems) was performed on the supernatants stored at -20 °C as follows:

[0629] (i) Capture antibody was diluted according to the Certificate of Analysis (CoA) and coated on a 96-well plate for 24 hours.

[0630] (ii) The wells were washed with a washing solution and then blocked with a 1% BSA (bovine serum albumin, Sigma) solution for 1 hour.

[0631] (iii) The wells were washed with a wash solution and the samples were then treated for 2 hours.

[0632] (iv) The wells were washed with washing solution, and then the detection antibody was diluted according to the certificate of analysis and aliquoted into the wells, and then treated with it for 2 hours.

[0633] (v) The wells were washed with a washing solution and then treated with streptavidin-HRP for 20 minutes.

[0634] (vi) The wells were washed with a wash solution and then treated with a substrate solution for 20 minutes.

[0635] (vii) Treat the wells with stop solution and measure the absorbance at 450 nm.

[0636] Example 3.2. Identification of cytokine secretion capacity in human T cells

[0637] Considering that IFN-γ (interferon-γ) secretion is a major immune response, IFN-γ secretion occurs when human T cells are treated with IL-12. The IFN-γ secretion capacity was evaluated when human T cells were treated with recombinant human IL-12, T1.12, T1.01, T1.02, and T1.03.

[0638] Specifically, human T cells activated with anti-CD3 (OKT3, Invitrogen) were diluted to 5 × 10 5Cells / ml were added and dispensed in 96-well plates at 200 μl / well. Recombinant human IL-12, T1.12, T1.01, T1.02, and T1.03 were diluted to 10 nM and dispensed at 20 μl / well. After 48 hours of treatment, cell supernatants were collected and samples were stored at -80°C.

[0639] The results are as follows Fig.21 As shown, samples treated with recombinant human IL-12 were found to have an average of 1,640 pg / ml of IFN-γ; samples treated with T1.01 had an average of 1,115 pg / ml of IFN-γ; samples treated with T1.02 had an average of 845 pg / ml of IFN-γ; and samples treated with T1.03 had an average of 607 pg / ml of IFN-γ. In contrast, samples treated with T1.12 as a control were found to have no IFN-γ.

[0640] These results indicate that T1.01, T1.02, and T1.03 act on human T cells to induce IFN-γ secretion.

[0641] Example 3.3. Identification of cytokine secretion capacity in human NK cells

[0642] Considering that IFN-γ (interferon-γ) secretion is a major immune response and IFN-γ secretion occurs when human NK cells are treated with IL-12, the present inventors evaluated the IFN-γ secretion capacity of human NK cells activated with recombinant human IL-2 (R&D systems) when treated with recombinant human IL-12, T1.12, T1.01, T1.02 and T1.03.

[0643] Specifically, human NK cells activated with recombinant human IL-2 (R&D Systems) were diluted to 5 × 10 5 Cells / ml, and dispensed in 96-well plates at 200 μl / well. Recombinant human IL-12, T1.12, T1.01, T1.02, and T1.03 were diluted to 10 nM and dispensed at 20 μl / well. After 24 hours of treatment, cell supernatants were collected and samples were stored at -80°C.

[0644] The results are as follows Fig. 22As shown, samples treated with recombinant human IL-12 were found to have an average of 180 pg / ml of IFN-γ; samples treated with T1.01 had an average of 205 pg / ml of IFN-γ; samples treated with T1.02 had an average of 133 pg / ml of IFN-γ; and samples treated with T1.03 had an average of 80 pg / ml of IFN-γ. In contrast, samples treated with T1.12 as a control were found to have no IFN-γ. These results indicate that T1.01, T1.02, and T1.03 act on human NK cells to induce IFN-γ secretion.

[0645] Example 4. Evaluation of the anticancer efficacy of fusion protein in colorectal cancer animal model

[0646] Example 4.1. Evaluation of anticancer efficacy in colorectal cancer animal models by co-injection of FAP-expressing fibroblasts

[0647] Considering that the fusion protein is a dual-antibody format with anti-FAP sequence structure and IL-12 sequence structure, and FAP is overexpressed in fibroblasts present in many tumor microenvironments, after overexpressing mouse FAP in the mouse fibroblast cell line NIH3T3 cells, the tumor growth inhibition ability was evaluated in a tumor animal model co-injected with CT26 (mouse colorectal cancer cell line) at a 1:1 ratio.

[0648] Mouse colorectal cancer cell line CT26 and mouse fibroblast cell line NIH-3T3 were used to prepare FAP-expressing tumor animal models. Then, NIH-3T3 was prepared as a FAP-expressing cell line.

[0649] Specifically, NIH-3T3 cells overexpressing mouse FAP and cultured CT26 cells were cultured at 1×10 6 The cells were resuspended in Hanks' balanced salt solution (HBSS, Gibco) at a concentration of 10 cells / 50 μl, and the cells were mixed at a ratio of 1:1, and then transplanted into the subcutaneous area of ​​the right flank of 6-week-old BALB / c mice using a 1cc syringe (25G) at 100 μl per mouse to obtain a FAP-expressing fibroblast co-injection animal model. Tumor size was measured using a digital vernier caliper by measuring the short and long axes of the tumor and expressed as (short axis, mm) 2 The tumor size was measured twice a week using the calculation formula × (long axis, mm) × 0.5.

[0650] Next, for drug efficacy evaluation, when the tumor size reaches 100 mm 3The mice were randomly divided into groups. Each experimental group consisted of 10 animals. As a control, 50 μg / 100 μl of T1.24m was intraperitoneally administered 3 times at intervals of 3 days. In the test group, 10 μg / 100 μl and 50 μg / 100 μl of T1.02m and 50 μg / 100 μl of T1.01m were intraperitoneally administered 3 times at intervals of 3 days, respectively, to evaluate the tumor growth inhibitory ability.

[0651] The results are as follows Fig.23 As shown, when comparing the tumor size on day 14, it was found that the groups administered with 10 μg and 50 μg of T1.02m had excellent tumor growth inhibition abilities of 93.2% and 92.7%, respectively, compared with the group administered with 50 μg of T1.24m as a control. In addition, it was observed that the group administered with 50 μg of T1.01m had tumor growth inhibition of 91.9%, compared with the group administered with 50 μg of T1.24m as a control.

[0652] In addition, if Fig.24 As shown, on day 24 after administration, more subjects with complete remission were observed in the groups administered with T1.01m and T1.02m compared with the control group.

[0653] These results indicate that the fusion protein of one embodiment has excellent anti-cancer efficacy in colorectal cancer animal models.

[0654] Example 4.2. Evaluation of anticancer efficacy in an animal model of colorectal cancer expressing FAP

[0655] In the case of colorectal cancer, considering the high expression of FAP in tumor cells themselves, in order to evaluate the anticancer effect, the tumor growth inhibitory ability was assessed in a tumor model in which mouse FAP overexpression was induced in the mouse colorectal cancer cell line CT26 cells.

[0656] To prepare a mouse tumor animal model expressing FAP, FAP overexpression was induced in the mouse colorectal cancer cell line CT26. Specifically, the FAP-overexpressing CT26 cells in culture were resuspended in Hanks' balanced salt solution (HBSS, Gibco), and then 1×10 cells / 100 μl per mouse were injected using a 1cc syringe (25G). 6 Tumor cells were transplanted into the left dorsal subcutaneous region of 6-week-old BALB / c mice to obtain a mouse colorectal cancer animal model expressing FAP. Tumor size was measured by measuring the short and long axes of the tumor using a digital vernier caliper and expressed as (short axis, mm) 2 The tumor size was measured twice a week using the calculation formula × (long axis, mm) × 0.5.

[0657] Next, for drug efficacy evaluation, when the tumor size reaches 100 mm3 The mice were randomly divided into groups. Each experimental group consisted of 8 animals. As a control, 50 μg / 100 μl T1.24m was intraperitoneally administered 4 times at intervals of 3 days. In the test group, 10 μg / 100 μl and 100 μg / 100 μl of T1.01m, and 2 μg / 100 μl, 10 μg / 100 μl, and 100 μg / 100 μl of T1.02m were intraperitoneally administered 4 times at intervals of 3 days, respectively, to evaluate the tumor growth inhibitory ability.

[0658] The results are as follows Fig.25 As shown, after 18 days of administration, the groups administered with 10 μg and 100 μg of T1.01m were found to have high tumor growth inhibition abilities of 84.9% and 85.6%, respectively, compared to the group administered with 50 μg of T1.24m as a control. In addition, it was observed that the groups administered with T1.02m had high tumor growth inhibition abilities of 80.1%, 90.5%, and 89.8%, respectively, compared to the group administered with T1.24m as a control.

[0659] In addition, it was identified that there were subjects with complete remission (CR) on day 30 after administration in each administration group, and tumor growth was inhibited, and no changes in body weight were observed during the test period according to the administration conditions. These results show that the fusion protein of one embodiment has excellent anti-cancer efficacy in colorectal cancer animal models.

[0660] Example 4.3. Evaluation of the fusion protein on the growth inhibition of recurrent solid cancer in mice with complete remission

[0661] To evaluate whether fusion protein treatment can suppress tumor recurrence by inducing long-term immune responses, tumor rechallenge was performed in subjects who achieved complete remission by administration of T1.01m in a tumor model transplanted with CT26 cells overexpressing FAP. BALB / c mice with no treatment history were used as control mice.

[0662] Tumor recurrence models were obtained by subcutaneously injecting 4T1 cells into the left flank of control mice and mice that achieved complete remission after receiving T1.01m, and by subcutaneously injecting CT26 cells into the right flank of control mice and mice that achieved complete remission after receiving T1.01m.

[0663] Specifically, in a model transplanted with CT26 cells, a tumor recurrence model was induced in mice, in which complete remission was shown by administration of T1.01m. CT26 cells and 4T1 cells were each administered at 1×10 6CT26 cells were suspended in Hanks' balanced salt solution (HBSS, Gibco) at a concentration of 1 cell / 100 μl and transplanted into the subcutaneous area of ​​the right flank of mice using a 1cc syringe (25G). The formation and growth of tumors were assessed by subcutaneous transplantation of 4T1 cells into the left flank of the same mice. Nine animals were used for the control group and seven animals were used for the test group.

[0664] The results are as follows Fig.26 and Fig. 27 As shown, it was found that both transplanted 4T1 tumors and CT26 tumors grew in control mice with no treatment history, while in mice that achieved complete remission after administration of T1.01m, 4T1 tumors grew, but the growth of CT26 tumors was inhibited. These results indicate that the fusion protein of one embodiment can inhibit tumor recurrence.

[0665] Example 4.4. Evaluation of reduced activity based on IL-12 amino acid mutations in fusion proteins

[0666] In order to reduce the in vivo toxicity caused by excessive activation of the immune system by IL-12, the present inventors used an IL-12 sequence structure containing a mutation in the amino acid sequence that binds to heparin to induce reduced activity by blocking the binding to the IL-12 receptor, and identified this through a tumor animal model.

[0667] Among the anti-FAP antibodies, T1.02m and T1.03m have amino acid mutations involved in heparin binding, and T1.01m is used as a control. Then, T1.02m has a mouse IL-12 sequence structure, which contains amino acid mutations (two) involved in heparin binding and an anti-FAP sequence structure. T1.03m is a fusion protein with an IL-12 sequence structure, which contains mutated (four) amino acids involved in heparin binding and an anti-FAP sequence structure.

[0668] To assess changes in IL-12 activity according to the presence and extent of amino acid mutations, 5 × 10 5 FAP-overexpressing mouse colorectal cancer CT26 was prepared by resuspending the cells at a concentration of 10 cells / 100 μl, and the tumor growth inhibition ability was evaluated in a tumor animal model prepared by transplanting the cells into 5-week-old female BALB / c mice.

[0669] Specifically, when the tumor size in the model reaches 100 mm 3 The mice were randomly divided into groups. The control group was injected once with 100 μl of phosphate buffered saline (PBS) through the tail vein, and T1.01m, T1.02m and T1.03m were intravenously administered once at a dose of 10 μg each.

[0670] The results are as follows Fig.28As shown, it was found that the T1.01m, T1.02m and T1.03m administration groups all had excellent tumor growth inhibition ability compared with the control group 15 days after administration.

[0671] In addition, it was found that the tumor growth inhibitory ability was reduced in the group administered with T1.03m (IL-12 and mouse anti-FAP sequence containing amino acid mutations (four) involved in heparin binding) compared with the group administered with T1.01m. These results indicate that the IL-12 activity in the group administered with T1.03m (IL-12 sequence structure containing amino acid mutations (four) involved in heparin binding) was reduced compared with the other experimental groups and the control group.

[0672] Example 4.5. Evaluation of the anticancer effect after a single administration of IL-12 amino acid mutation fusion protein

[0673] To evaluate the anticancer effect of the fusion protein with reduced IL-12 activity due to the sequence structure containing amino acid mutations (four) involved in heparin binding, the tumor growth inhibitory ability was evaluated in a tumor model transplanted with FAP-overexpressing mouse colorectal cancer cell line CT26 cells.

[0674] Specifically, tumor cells were transplanted into the right dorsal flank of 6-week-old BALB / c mice. When the tumor size of the animal model reached 70 mm 3 Up to 100mm 3 The mice were randomly divided into groups and administered. As a control, PBS was administered, and as a test group, 100 μl of T1.03m was intravenously administered once at a dose of 2 μg, 10 μg, and 100 μg. The size of the tumor was measured in the same manner as in Example 4.1.

[0675] The results are as follows Fig.29 As shown, it was observed that the groups administered with 2 μg, 10 μg, and 100 μg of T1.03m had higher tumor growth inhibition ability compared with the control group. No weight change was observed during the test period. These results indicate that T1.03m reduces IL-12 activity due to its sequence structure containing amino acid mutations (four) involved in heparin binding, and has excellent anti-cancer efficacy at a certain concentration or higher.

[0676] Example 5. Evaluation of the anticancer efficacy of fusion protein in melanoma animal model

[0677] To identify the anticancer effect of the fusion protein through immune activation, mouse FAP was overexpressed in the mouse melanoma cell line B16F10, which is known to have less immune cell infiltration, and then transplanted into C57BL / 6J mice, and the tumor growth inhibitory ability was evaluated.

[0678] Specifically, the cultured cells were resuspended in Hanks' balanced salt solution (HBSS, Gibco) and then 1 × 10 6 Tumor cells were implanted into the subcutaneous area of ​​the left dorsal flank of 6-week-old C57BL / 6J mice.

[0679] Next, for drug efficacy evaluation, when the tumor size reached 70 mm 3 Up to 100mm 3 As a control, PBS was administered, and as a test group, T1.03m was intravenously administered once at a dose of 10 μg and 100 μg.

[0680] The results are as follows Fig.30 As shown, it was observed that both groups given 10 μg and 100 μg of T1.01m had higher tumor growth inhibition ability compared with the control. No weight change was observed during the test period. These results indicate that T1.03m has excellent anti-cancer efficacy even in melanoma animal models, as it reduces IL-12 activity due to its sequence structure containing amino acid mutations (four) involved in heparin binding.

[0681] Example 6. Evaluation of the anticancer efficacy of fusion protein in lung cancer animal model

[0682] Example 6.1. Evaluation of the anticancer efficacy of IL-12 amino acid mutation fusion protein in lung cancer animal model

[0683] Considering that FAP is overexpressed in fibroblasts present in the microenvironment surrounding the tumor, FAP was overexpressed in mouse fibroblast cell line NIH-3T3 cells and then co-injected with mouse lung cancer cell line LLC1 cells at a 1:1 ratio to prepare a tumor animal model and evaluate the tumor growth inhibitory ability.

[0684] Specifically, NIH-3T3 cell line and LLC1 cells overexpressing FAP were cultured at 1×10 6 The cells were resuspended in Hanks' balanced salt solution (HBSS, Gibco) at a concentration of 10 cells / 50 μl, and the cells were mixed at a 1:1 ratio and then transplanted into the subcutaneous area of ​​the right flank of 6-week-old C57BL / 6J mice at 100 μl per mouse using a 1 cc syringe (25G).

[0685] Next, for drug efficacy evaluation, when the tumor size reached 70 mm 3 Up to 100mm 3 As a control, PBS was administered, and as a test group, T1.03m was intravenously administered once at a dose of 10 μg and 100 μg.

[0686] The results are as follows Fig.31 As shown, it was observed that both groups given 10μg or 100μg of T1.03m had excellent tumor growth inhibition ability compared with the control group. No weight change was observed during the test. These results indicate that T1.03m reduces IL-12 activity due to a sequence structure containing amino acid mutations (four) involved in heparin binding. T1.03m recognizes target factors of the tumor microenvironment and, therefore, has excellent anti-cancer efficacy even in lung cancer animal models.

[0687] Example 6.2. Evaluation of cancer targeting efficacy in lung cancer animal models by fusion protein co-injection

[0688] To compare the anti-cancer efficacy of the dual-antibody fusion protein based on the cancer targeting of the anti-FAP sequence structure and the IL-12 sequence structure forming a knob-in-hole structure, the tumor growth inhibition ability was identified in an animal model of co-injection (ratio of 1:1) of NIH-3T3 cells (mouse fibroblast cell line) overexpressing FAP and LLC1 (mouse lung cancer cell line).

[0689] Specifically, for drug efficacy evaluation, when the tumor size reaches 70 mm 3 Up to 100mm 3 The mice were randomly divided into groups. As a control, PBS was intraperitoneally administered twice a week. The T1.16m or T1.17m single administration group, the T1.16m and T1.17m combined administration group (T1.16m+T1.17m), and the T1.03m group were used as experimental groups to evaluate the tumor growth inhibition ability. T1.16m and T1.17m are dimers of anti-FAP and IL-12, respectively, and are intraperitoneally administered twice a week at a dose of 0.01μg. T1.03m is a monomeric fusion protein, and is intraperitoneally administered twice a week at a dose of 0.02μg to observe the tumor growth inhibition ability.

[0690] The results are as follows Fig.32 As shown, it was observed that the T1.03m administration group had excellent tumor growth inhibition ability at the time point of 10 days after administration compared with the control. The group administered with T1.16m or T1.17m alone was compared with each combined administration group, and it was found that the group administered with T1.03m alone had excellent tumor growth inhibition ability. These results show that the synergistic effect of the fusion protein of one embodiment is significant compared with the case of targeting FAP alone or with IL-12 without cancer targeting.

[0691] Example 7. Confirmation of anticancer effect when fusion protein and anticancer agent are co-administered

[0692] Example 7.1. Co-administration of immune checkpoint inhibitors in a lung cancer mouse model to confirm anti-cancer effects

[0693] In order to compare the anti-cancer efficacy of the fusion protein in which the anti-FAP sequence structure and the IL-12 sequence structure form a knob-in-hole structure and the immune checkpoint inhibitor, the ability to inhibit tumor growth was confirmed in a mouse animal model. Specifically, a mouse animal model was used in which NIH-3T3 cells, a mouse fibroblast cell line overexpressing FAP, and LLC1, a mouse lung cancer cell line, were co-injected at a ratio of 1:1.

[0694] For drug efficacy evaluation, when the tumor size reaches an average of 110 mm 3 Up to 120mm 3 They were randomly divided into groups and PBS was intraperitoneally administered once every 3 days for a total of three times as a control group. The T1.03m single-dose group, the immune checkpoint inhibitor aPD-L1 (clone 10F.9G2, BioXCell), aCTLA-4 (clone 9D9, BioXCell) or aPD-1 (clone RMP1-14, BioXCell) single-dose group, T1.03m and aPD-L1 co-administration ( Fig.33a ), T1.03m and aCTLA-4 co-administration ( Figure 33b ) and T1.03m and aPD-1 co-administration group ( Fig.33c ) was used as an experimental group to evaluate the tumor growth inhibition ability. T1.03m was intravenously injected once at a dose of 10 μg, and the immune checkpoint inhibitor was administered once every 3 days at a dose of 200 μg, and the tumor growth inhibition ability was observed.

[0695] The results are as follows Figures 33a to 33c As shown, superior tumor growth inhibition was observed in the immune checkpoint inhibitor co-administration group compared with the control group and T1.03m administration group 9 days after administration. These results indicate that anti-FAP and IL-12 monomeric fusion protein T1.03m has a significant synergistic effect in the lung cancer mouse model when co-administered with immune checkpoint inhibitors.

[0696] Example 7.2. Co-administration of immune checkpoint inhibitors in a colon cancer mouse model to confirm anti-cancer effects

[0697] In order to compare the anti-cancer efficacy of a bispecific antibody fusion protein in which the anti-FAP sequence structure and the IL-12 sequence structure form a knob-in-hole structure and are co-administered with an immune checkpoint inhibitor, the tumor growth inhibition ability was confirmed in a mouse animal model. Specifically, a mouse animal model was used in which NIH-3T3 cells, a mouse fibroblast cell line overexpressing FAP, and MC38, a mouse colon cancer cell line, were co-injected at a ratio of 1:1.

[0698] Specifically, for drug efficacy evaluation, when the tumor size reaches an average of 90 mm 3 Up to 160mm3 When the cells were treated with PBS, they were randomly divided into groups and PBS was administered intraperitoneally once every 3 days as a control group. The immune checkpoint inhibitors of the T1.03m single-dose group, the aPD-L1 (clone 10F.9G2, BioXCell) single-dose group, and the T1.03m and aPD-L1 co-administration group were used as experimental groups to evaluate the tumor growth inhibition ability. T1.03m was injected intravenously once at a dose of 2 μg, and the immune checkpoint inhibitors were administered once every 3 days at a dose of 200 μg, and the tumor growth inhibition ability was observed.

[0699] The results are as follows Fig.34a and Fig.34b As shown, at 16 days after administration, superior tumor growth inhibition was observed in the immune checkpoint inhibitor co-administration group compared with the control group and T1.03m administration group. These results indicate that anti-FAP and IL-12 monomeric fusion protein T1.03m has a significant synergistic effect in the colon cancer mouse model when co-administered with immune checkpoint inhibitors.

[0700] In addition, in order to further evaluate the tumor growth inhibitory ability, the T1.03m single-dose group, the aPD-L1 (clone 10F.9G2, BioXCell) single-dose group of immune checkpoint inhibitors, and the T1.03m and aPD-L1 co-administration group were used as experimental groups, T1.03m was intravenously injected once at a dose of 10 μg, and the immune checkpoint inhibitor was administered once every 3 days at a dose of 200 μg, and the tumor growth inhibitory ability was observed.

[0701] The results are as follows Fig.35a and Fig.35b As shown, at 11 days after administration, excellent tumor growth inhibition ability was observed in the immune checkpoint inhibitors in the aPD-L1 co-administration group compared with the control group and the T1.03m administration group.

[0702] In addition, T1.03m single administration group, aTIGIT (clone 1G9, BioXCell), aLAG-3 (clone C9B7W, BioXCell) or aTIM-3 (clone RMT3-23, BioXCell) single administration group, T1.03m and aTIGIT co-administration (Figure 36), T1.03m and aLAG-3 co-administration (Figure 37), and T1.03m and aTIM-3 co-administration group (Figure 38) were used as experimental groups to evaluate tumor growth inhibition ability. T1.03m was injected intravenously once at a dose of 10 μg, and immune checkpoint inhibitors were administered once every 3 days at a dose of 200 μg, and tumor growth inhibition ability was observed.

[0703] The results are as follows Fig.36a and Fig.36bAs shown, at 10 days after administration, excellent tumor growth inhibition ability was observed in the T1.03m and aTIGIT co-administration group compared with the control group and the T1.03m single administration group.

[0704] In addition, if Fig.37a and Figure 37b As shown, at 10 days after administration, excellent tumor growth inhibition ability was observed in the T1.03m and aLAG-3 co-administration group compared with the control group and the T1.03m single administration group.

[0705] In addition, if Fig.38a and Figure 38b As shown, at 10 days after administration, excellent tumor growth inhibition ability was observed in the T1.03m and aTIM-3 co-administration group compared with the control group and the T1.03m single administration group.

[0706] These results demonstrate that the anti-FAP and IL-12 monomeric fusion protein T1.03m has a significant synergistic effect in a mouse model of colon cancer when co-administered with immune checkpoint inhibitors.

[0707] Example 7.3. Co-administration of chemical anticancer agents in a colon cancer mouse model to confirm anticancer effects

[0708] In order to compare the anti-cancer efficacy of the bispecific antibody format fusion protein in which the anti-FAP sequence structure and the IL-12 sequence structure form a knob-in-hole structure and a chemical anticancer agent when co-administered, the tumor growth inhibition ability was confirmed in a mouse animal model. Specifically, a mouse animal model was used in which NIH-3T3 cells, a mouse fibroblast cell line overexpressing FAP, and MC38, a mouse colon cancer cell line, were co-injected at a ratio of 1:1.

[0709] Specifically, for drug efficacy evaluation, when the tumor size reaches an average of 110 mm 3 Up to 120mm 3When the cells were treated with PBS, they were randomly divided into groups and PBS was intraperitoneally administered once every 4 days as a control group. T1.03m single administration group: single administration of chemical anticancer agents cyclophosphamide (Endoxan injection, Bukwang Pharm. Co., Ltd.), fluorouracil (5-FU injection, JW Pharmaceutical), paclitaxel (Neotax injection, JW Pharmaceutical) or Camptosar (irinotecan injection, Pfizer); T1.03m and cyclophosphamide co-administration group (Figure 39), T1.03m and fluorouracil co-administration group (Figure 40), T1.03m and paclitaxel co-administration group (Figure 41), and T1.03m and Camptosar co-administration group (Figure 42) were used as experimental groups, and the tumor growth inhibition ability was evaluated.

[0710] The results are as follows Fig.39a and Fig.39b As shown, at 11 days after administration, excellent tumor growth inhibition ability was observed in the T1.03m and cyclophosphamide co-administration group compared with the control group and the T1.03m single administration group.

[0711] In addition, if Fig.40a and Fig.40b As shown, at 11 days after administration, excellent tumor growth inhibition ability was observed in the T1.03m and fluorouracil co-administration group compared with the control group and the T1.03m single administration group.

[0712] In addition, if Fig.41a and Fig.41b As shown, at 11 days after administration, excellent tumor growth inhibition ability was observed in the T1.03m and paclitaxel co-administration group compared with the control group and the T1.03m single administration group.

[0713] In addition, if Fig.42a and Figure 42b As shown, at 11 days after administration, excellent tumor growth inhibition ability was observed in the T1.03m and Camptosar co-administration group compared with the control group and the T1.03m administration group.

[0714] These results suggest that the anti-FAP and IL-12 monomeric fusion protein T1.03m has a significant synergistic effect in a mouse model of colon cancer when co-administered with chemotherapeutic anticancer agents.

Claims

1. A pharmaceutical composition for preventing or treating cancer, comprising: A fusion protein comprising a first monomer containing IL-12 or a variant thereof and a second monomer containing an antigen binding site that specifically binds to FAP (fibroblast activation protein alpha); and Anticancer agent.

2. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The IL-12 or variants thereof include IL-12A (p35) or a variant thereof; and IL-12B (p40) or a variant thereof.

3. The pharmaceutical composition for preventing or treating cancer according to claim 2, wherein: The variant of IL-12B (p40) comprises an amino acid sequence obtained by one or more substitutions selected from the group consisting of K258A, K260A, K263A and K264A in the amino acid sequence shown in SEQ ID NO:

74.

4. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The first monomer and the second monomer form a knob-into-hole structure.

5. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The anticancer agent is selected from any one of the group consisting of chemical anticancer agents, anticancer viruses and immune checkpoint inhibitors.

6. The pharmaceutical composition for preventing or treating cancer according to claim 5, wherein: The chemical anticancer agent is any one selected from the group consisting of alkylating agents, microtubule inhibitors, antimetabolites and topoisomerase inhibitors.

7. The pharmaceutical composition for preventing or treating cancer according to claim 5, wherein: The chemical anticancer agent is any one selected from the group consisting of cyclophosphamide, cisplatin, fluorouracil, gemcitabine, camptosar, paclitaxel and doxorubicin.

8. The pharmaceutical composition for preventing or treating cancer according to claim 5, wherein: The anticancer virus is talimogene laherparepvec (T-VEC).

9. The pharmaceutical composition for preventing or treating cancer according to claim 5, wherein: The immune checkpoint inhibitor is selected from any one of the group consisting of anti-CTLA-4 antibody, anti-PD-1 antibody, anti-PD-L1 antibody, anti-TIM3 antibody, anti-TIGIT antibody and anti-LAG3 antibody.

10. The pharmaceutical composition for preventing or treating cancer according to claim 5, wherein: The immune checkpoint inhibitor is selected from any one of the group consisting of ipilimumab, pembrolizumab, nivolumab, cemiplimab, atezolizumab, avelumab and durvalumab.

11. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein: The cancer is selected from any one of the group consisting of gastric cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, acute myeloid leukemia, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, melanoma, bladder cancer, esophageal cancer, head and neck cancer, skin cancer, colorectal cancer and lymphoma.

12. A kit for preventing or treating cancer, comprising A fusion protein comprising a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP; and Anticancer agents as active ingredients.

13. A method for preventing or treating cancer, comprising The step of administering to a subject a fusion protein or a dimer thereof and an anticancer agent, wherein the fusion protein comprises a first monomer comprising IL-12 or a variant thereof and a second monomer comprising an antigen binding site that specifically binds to FAP.

Citation Information

Patent Citations

  • Antibody-drug conjugates and immunotoxins

    US20170007716A1

  • Multispecific proteins

    US20200385488A1

  • Flow rate measuring system with calibration means

    US3924445A

  • Anti-FAP antibodies and methods of use

    US9011847B2

  • Activated stromal fibroblast-specific antibody, f19 and methods of using the same

    WO1993005804A1